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The first accounts of investigation into the pharmacological effects of 
Cannabis sativa can be found in Chinese oral tradition dating back to 2700 B.C. 
In the book Shen Nong Ben Cao Jing, cannabis was noted to stimulate appetite 
and produce hallucinatory and antisenility effects (Shou-Zhong, 1997). Modern 
research on the pharmaceutical properties of the cannabis plant began with the 
isolation and synthesis of delta-9-tetrahydrocannabinol (THC) by Gaoni and 
Mechoulam (1964). THC has been found to produce most of the desired 
psychoactive effects of cannabis through the stimulation of the cannabinoid 
type 1 receptor (CB1; Grotenhermen, 2003). This has led to the development of 
cannabis strains containing high amounts of this compound through the use of 
modern hydroponic cannabis farms (Hardwick and King, 2008). Consequently, 
it has been claimed that the availability of THC-abundant cannabis plants 
could result in more severe effects of abuse, since THC has been connected with 
the emergence of anxiety (Hunault et al., 2014) and psychotic episodes both in 
an acute intoxicated state (D’Souza et al., 2004) and in the long-term (Kuepper 
et al., 2010). However, since the discovery of THC, over 100 other natural 
compounds, called cannabinoids, have been isolated from the plant (ElSohly 
and Gul, 2014). Up-to-date research indicates that cannabidiol (CBD), the 
major constituent of the non-psychoactive (fiber-type) variety of cannabis, 
produces effects which are in contrast to those induced by THC (Bhattacharyya 
et al., 2010). CBD has been shown to act as a partial antagonist at CB1 
receptors (Pertwee, 2008) and as an agonist at serotonin receptors (5-HT; 
Campos and Guimarães, 2008; Zanelati et al., 2010; Gomes et al., 2011). CBD 
also stimulates the vanilloid receptor type 1 (VR1) with a maximum effect 
similar in efficacy to that of capsaicin (Bisogno et al., 2001). Moreover, CBD 
has been shown to have anxiolytic (e.g., Zuardi et al., 1982, 1993; Crippa et al., 
2004, 2011; Fusar-Poli et al., 2009; Bergamaschi et al., 2011) and antipsychotic 
effects in humans (e.g., Zuardi et al., 2009; Bhattacharyya et al., 2010; 
Schubart et al., 2011). In addition, there is evidence that CBD modulates the 
effects of THC by affecting its absorption, distribution, and metabolism 
(McPartland and Russo, 2014). 
Aside of cannabinoids, the cannabis plant also contains terpenoids—the 
compounds responsible for the smell and taste of cannabis (McPartland and 
Russo, 2014). Terpenoids have been identified to affect the pharmacokinetics of 
THC by inducing vasodilatation of alveolar capillaries (thus increasing THC 
absorption by the lungs) and enhancing blood–brain barrier penetrability 













(Agrawal et al., 1989). In addition, research points to analgesic, anti-
inflammatory, and neuroprotective properties of specific terpenoids present in 
cannabis (Russo, 2011). In sum, although sufficient research is still lacking, 
both CBD, as well as terpenoids, can be considered as “entourage compounds” 
in cannabis, due to their interactions with THC (Russo, 2011; McPartland and 
Russo, 2014). Consequently, in contrast to many other recreational drugs 
containing only one active compound, the pharmacological complexity of 
cannabis makes it more difficult to investigate the psychoactive effects of the 
plant, as well as a fascinating topic of study that highlights many research 
opportunities. 
Cognitive effects of cannabis 
In spite of the abundance of different compounds present in cannabis, 
THC has been found to have the most significant impact on cognition (Curran 
and Morgan, 2014). The discovery of the endocannabinoid system through the 
identification of the CB1 receptor (Devane et al., 1988; Matsuda et al., 1990) 
and the first endogenous cannabinoid (anandamide, AEA; Devane et al., 1992) 
opened the doors for a better understanding of the biological mechanisms 
behind the cognitive effects of cannabis. Research points to complex 
pharmacological interactions between the endocannabinoid and dopamine (DA) 
systems as one of the mechanisms through which THC affects cognitive 
processes. Specifically, CB1 receptors, which are widely distributed in the brain, 
indirectly modulate the release of DA through the inhibition and stimulation of 
Gamma Amino Butyric Acid (GABA) and glutamate neurons (Gerdeman et al., 
2003; Fattore et al., 2010; Fernández-Ruiz et al., 2010). Moreover, research 
shows that repeated stimulation of CB1 receptors leads to the decrease in their 
density in the brains of chronic cannabis users (Hirvonen et al., 2012). As a 
consequence, the effects which THC has on cognition differ between 
experienced and infrequent users. In particular, it has been demonstrated that 
smoking of THC-rich cannabis joints by chronic cannabis users does not lead to 
impairments in cognitive flexibility, mental calculation, and reasoning (Hart et 
al., 2001), or in episodic and working memory (Hart et al., 2010). Moreover, 
although infrequent users have been found to display impaired tracking 
performance and attentional processes following THC administration, the same 
has not been observed in regular cannabis users (Ramaekers et al., 2009; 





similarly impaired among both populations when intoxicated with cannabis 
(Ramaekers et al., 2009). 
As for CBD, the way that it influences cognition is less clear. Some 
researchers (e.g. Schier et al., 2012) have claimed that CBD has no effect on 
cognitive processes. Nonetheless, research shows that CBD has contradictory 
effects to THC on the activation of brain regions during response inhibition 
(Borgwardt et al., 2008), emotional processing (Fusar-Poli et al., 2009), and 
verbal memory (Bhattacharyya et al., 2010). Combining this with the memory-
protecting properties of CBD against the impairing effects of THC (Morgan et 
al., 2010, 2012), it may be claimed that CBD is a potent modulator of the 
cognitive impact of THC. On the other hand, the data available on the cognitive 
effects of pure CBD is scarce, aside from a recent study showing enhancement 
of emotional facial affect recognition after CBD administration (Hindocha et al., 
2015). 
Outline of this thesis 
The main goal of this thesis is to present novel insight into the impact 
of cannabis on cognitive functions and their neural correlates. Specifically, this 
thesis contains three empirical chapters and one review chapter on both the 
acute and chronic effects of cannabis on mental and neural processes.  
Chapter 2 investigated the effects of chronic use of cannabis on striatal 
dopaminergic functioning. In this study, regular cannabis users were compared 
with non-users controls with regard to their spontaneous eye blink rate 
(EBR)—an indirect marker of DA transmission in the striatum. 
Chapter 3 examined the acute impact of cannabis on creativity. The 
experiment included chronic users who were administered cannabis with 
different concentrations of THC using a vaporizer and tested on tasks tapping 
into divergent and convergent thinking. 
Chapter 4 investigated the acute effects of cannabis on the neural 
correlates of error monitoring. This study investigated how different doses of 
vaporized THC-rich cannabis affected the amplitudes of two event-related 
potentials (ERPs) associated with the cognitive processing of errors—the error-
related negativity (ERN) and error positivity (Pe). 
Chapter 5 reviewed the available neuroimaging research on the impact 
of CBD on cognitive and emotional processing. In particular, the putative role 
of the anterior cingulate cortex (ACC) as a critical modulator of the effects of 













CBD on brain connectivity was examined and potential implications of ACC 
involvement were discussed. 
Finally, chapter 6 summarizes the results of all the empirical studies 
presented in this thesis together with the conclusions of the review. In addition, 
the implications of the results are discussed and suggestions for future 
research are presented. 
 
The references to the published chapters are presented below: 
Chapter 2: Kowal MA, Colzato LS, Hommel B (2011) Decreased 
spontaneous eye blink rates in chronic cannabis users: evidence for striatal 
cannabinoid-dopamine interactions. PLoS ONE 6:e26662. DOI: 
10.1371/journal.pone.0026662 
Chapter 3: Kowal MA, Hazekamp A, Colzato LS, van Steenbergen H, 
van der Wee NJA, Durieux J, Manai M, Hommel B (2015a) Cannabis and 
creativity: highly potent cannabis impairs divergent thinking in regular 
cannabis users. Psychopharmacology 232:1123-1134. DOI: 10.1007/s00213-014-
3749-1 
Chapter 4: Kowal MA, van Steenbergen H, Colzato LS, Hazekamp A, 
van der Wee NJA, Manai M, Durieux J, Hommel B (2015b) Dose-dependent 
effects of cannabis on the neural correlates of error monitoring in frequent 
cannabis users. European Neuropsychopharmacology 25:1943-1953. DOI: 
10.1016/j.euroneuro.2015.08.001 
Chapter 5: Kowal MA, Hazekamp A, Colzato LS, van Steenbergen H, 
Hommel B (2013) Modulation of cognitive and emotional processing by 
cannabidiol: the role of the anterior cingulate cortex. Frontiers in Human 









The effects of chronic cannabis 
use on striatal dopaminergic 
functioning* 
  
                                                             
* This chapter is based on: 
Kowal MA, Colzato LS, Hommel B (2011) Decreased spontaneous eye blink 
rates in chronic cannabis users: evidence for striatal cannabinoid-dopamine 
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Chronic cannabis use has been shown to block long-term depression of 
gamma amino butyric acid (GABA)-glutamate synapses in the striatum, which 
is likely to reduce the extent to which endogenous cannabinoids modulate 
GABA- and glutamate-related neuronal activity. The current study aimed at 
investigating the effect of this process on striatal dopamine levels by studying 
the spontaneous eye blink rate (EBR), a clinical marker of dopamine levels in 
the striatum. Twenty-five adult regular cannabis users and 25 non-user 
controls matched for age, gender, race, and IQ were compared. The results 
showed a significant reduction in the EBR of chronic users from that of non-
users, suggesting an indirect detrimental effect of chronic cannabis use on 
striatal dopaminergic functioning. Additionally, EBR correlated negatively 
with years of cannabis exposure, monthly peak cannabis consumption, and 
lifetime cannabis consumption, pointing to a relationship between the degree of 

















Cannabis (Cannabis sativa) is the most widely used illicit drug in 
Europe and the US. Its recreational use dates back to over 2000 B.C. The 
active compounds in cannabis are called exogenous cannabinoids, with delta-9-
tetrahydrocannabinol (THC) and cannabidiol (CBD) being responsible for most 
of the drug’s psychoactive effects (Earleywine, 2002). Current research 
indicates that THC, as a cannabinoid CB1 receptor agonist, indirectly affects 
dopaminergic functioning. Stimulation of the cannabinoid receptor type 1 (CB1) 
results in the release of dopamine (DA) (Gerdeman et al., 2003)—a 
neurotransmitter involved in the control of goal-directed behavior, reward 
learning, reinforcement, and addiction (Fattore et al., 2010). However, CB1 
receptors are not present at dopaminergic neurons. Instead, they are located in 
gamma amino butyric acid (GABA) and glutamatergic terminals which, in turn, 
influence DA/D1 and DA/D2 neurons by controlling DA inhibition. In other 
words, CB1 receptors contribute to the release of DA by inhibiting DA 
inhibitors.  
Interestingly, the highest concentrations of CB1 receptors in the brain 
can be observed at the same areas where dopaminergic neurons are present 
(Fattore et al., 2010). Crucial regions in this regard seem to be the basal 
ganglia and, more specifically, the striatum, in which endogenous cannabinoids 
modulate the firing of DA neurons. This occurs through postsynaptic 
interactions between cannabinoids and DA at the level of G-protein/adenylyl 
cyclase signal transduction (Fernández -Ruiz et al., 2010). As a consequence, it 
makes sense to assume that any effect of THC on DA transmission is the 
product of an indirect process. This is different from the impact of other often 
abused drugs, like amphetamine or cocaine, which seem to act directly on DA 
neurons (for a discussion, see: Colzato et al., 2008).  
Hitherto, two studies using positron emission tomography have looked 
into the acute effect of THC on striatal DA transmission—with, however, 
inconsistent results: one study reported a THC-induced increase in striatal DA 
level (Bossong et al., 2009) while another found no effect (Stokes et al., 2009). 
Things are even less clear with regard to chronic effects of long-term exposure 
to THC, on which no data are available. This is particularly unfortunate in 
view of Kuepper’s et al. (2010) suggestion that repeated THC administration 
may create a dopaminergic imbalance in the brain by increasing striatal DA 
levels but lowering DA levels in the prefrontal cortex. As a possible 
consequence of this imbalance, chronic THC exposure has been assumed to 




induce psychotic symptoms in users (Kuepper et al., 2010). However, a problem 
with this assumption is that it is not based on any evidence regarding chronic 
effects of THC on striatal DA transmission, but on only one finding regarding 
the acute effects level (Bossong et al., 2009). Therefore, it is not clear whether 
THC actually induces long-term dopaminergic imbalances. 
To address this issue, the present study aimed to investigate the effect 
of long-term exposure to cannabis on striatal DA transmission. In the case of 
chronic effects, it is difficult to differentiate between the specific psychoactive 
plant components which caused the potential impairments. Consequently, we 
use the more generic term “cannabis” in the present study, even though the 
available data suggest that the observed effects are mainly due to the impact of 
THC. For one, from the two main studied psychoactive compounds of cannabis, 
only THC acts as a CB1 receptor agonist, while CBD functions as an antagonist. 
For another, CBD is suspected to reduce the psychotic effects of THC, which 
would suggest a role of CBD in diminishing the potential DA-impairing effects 
of THC (Morgan et al., 2010). Nevertheless, for the sake of precision, no 
reference to specific cannabinoids is made. 
We assessed dopaminergic functioning by means of spontaneous eye 
blink rates (EBRs), a well-established clinical marker of striatal DA production 
(Karson, 1983; Shukla, 1985; Taylor et al., 1999). Numerous observations have 
helped to validate EBR as a measure of striatal DA functioning. For instance, 
deviant levels of EBR have been reported from patients suffering from DA-
related impairments: while EBR is elevated in schizophrenic patients, who 
exhibit increased striatal DA transmission (Freed, 1980), EBR is lowered in 
Parkinson’s patients, who have a reduced amount of nigrostriatal dopaminergic 
neurons (Deuschel and Goddemeier, 1998). In addition, EBRs vary as a 
function of the DRD4/7 genotype, which is associated with the modulation of 
DA levels in the striatum (Dreisbach et al., 2005). Moreover, nonhuman 
primate research has shown that direct DA agonists and antagonists increase 
and decrease EBRs, respectively (Kleven and Koek, 1996).  
Exact predictions of how chronic cannabis use might affect the striatal 
DA level—and the associated EBR—can be derived from animal research. 
Hoffman et al. (2003) showed that, in rats, chronic treatment with a CB1 
receptor agonist results in a reduced sensitivity of CB1 receptors located at 
glutamatergic and GABAergic terminals. Moreover, chronic application of THC 
completely blocks long-term depression (LTD) of GABA-glutamate synapses in 
the striatum. Normally, the regulatory role of LTD is to inhibit the activity of 














neurons, which again allows for DA transmission. Consequently, blocking LTD 
should reduce the extent to which endogenous cannabinoids modulate GABA 
and glutamate neuron activity. Moreover, the LTD–DA relationship appears to 
be bidirectional: striatal DA neurons are capable of synthesizing endogenous 
cannabinoids, which induce LTD and interact with DA as a supplementary 
inhibitory feedback mechanism (Fattore et al., 2010; Fernández-Ruiz et al., 
2010). However, in the case of chronic cannabis use, the decreased sensitivity of 
CB1 receptors implies that the likelihood of endogenous cannabinoids evoking 
LTD is lowered. As a result of this bidirectional process, chronic application of 
exogenous cannabinoids present in cannabis could be expected to lead to 
decreased DA transmission due to long-term, maladaptive inhibition by GABA 
and glutamate (Hoffman et al., 2003). If so, we would expect a decrease of the 
spontaneous EBR in chronic cannabis users from that in non-users 
Results 
EBR per minute was significantly lower in the chronic cannabis users 
(M = 10.24; SD = 5.861) than in the non-user controls (M = 17.52; SD = 9.019), 
t(48) = 3.384, p < 0.01. The same effect was obtained from an ANOVA with 
group (chronic cannabis users vs. non-user controls) as an independent variable 
and IQ and cigarette use as covariates: while the group effect was again 
significant, F(1, 46) = 5.477, p < 0.05, the covariate effects were not.  
To test whether the EBR in the chronic cannabis users was related to 
their consumption history and habits, Spearman’s Rho correlation coefficients 
were calculated between EBR/minute and the years of cannabis exposure, age 
of onset, monthly regular, monthly peak, and lifetime cannabis consumption. 
EBR correlated negatively with years of exposure, r(25) = −0.42, p < 0.05 (see 
Figure 1), monthly peak consumption, r(25) = −0.43, p < 0.05 (see Figure 2), 
and lifetime consumption, r(25) = −0.40, p < 0.05 (see Figure 3), while no 
significant correlations were found for age of onset, r(25) = −0.04, p = n.s., and 
monthly regular consumption, r(25) = −0.25, p = n.s. 
 




Figure 1 Years of cannabis exposure as a function of spontaneous eye blink rate 
per minute.  
Figure 2 Peak monthly cannabis consumption (in joints) as a function of 















Figure 3 Lifetime cannabis consumption (in joints) as a function of spontaneous 
eye blink rate per minute. 
Discussion 
The results of the study show a significant reduction of spontaneous 
EBR in chronic cannabis users from that in non-user controls. This can be 
interpreted as an indication of a dopaminergic hypoactive state in the striatum 
(Karson, 1983; Shukla, 1985; Taylor et al., 1999). Additionally, a moderate 
negative correlation between EBR and years of cannabis exposure suggests 
that the degree of impairment of DA transmission is, to a certain extent, 
proportional to the period of cannabis use. Conversely, the lack of a correlation 
between EBR and the age of onset of cannabis consumption suggests that 
starting to use marijuana at an earlier age does not contribute to the level of 
dopaminergic hypoactivity. However, such a claim should be treated with 
caution due to the fact that adolescent cannabis use has been linked to specific 
cognitive impairments, like less efficient discrimination between relevant and 
irrelevant stimuli (Abdullaev et al., 2010). In any case, it can be assumed that 
the striatal dopaminergic hypoactive state of chronic cannabis users is the 
result of blocking the supplementary inhibitory mechanism of LTD. The 
impairment of GABA and glutamate neuron activity combined with the 
downregulation of CB1 receptors seem to be plausible explanations for the 




observed decreased EBR in chronic users (Hoffman et al., 2003; Fattore et al, 
2010; Fernández-Ruiz et al., 2010). 
In the case of the modest negative correlation between EBR and 
monthly peak cannabis use, it could be inferred that a more pronounced binge 
use of marijuana has an additional detrimental impact on the level of DA in the 
striatum. However, DA impairment was found not to be related to the regular 
amount of cannabis consumed per month. A possible explanation for this effect 
comes from the research by Bolla et al. (1998), who identified organic drug 
exposure intensity, instead of duration, as a key factor in developing drug-
related neurocognitive deterioration. Therefore, it seems plausible to assume 
that binge use of cannabis is a better predictor of DA impairment than regular 
consumption is. Additionally, the moderate negative correlation between EBR 
and lifetime cannabis consumption suggests that the degree of impairment of 
striatal dopaminergic functioning is related to the total amount of cannabis 
consumed during a lifetime. Possibly, use of higher doses of cannabis, both in 
the short- and long-term, has a more detrimental enduring effect on GABA and 
glutamate inhibition of DA in striatum than the impact of using smaller doses 
for a longer period of time. 
As for the limitations of the present study, one is the lack of additional 
verification of participants’ compliance with the no-consumption instructions. 
Subjects’ urinary or plasma levels of THC metabolites (THC-COOH) were not 
examined to confirm cannabis use status. Another limitation is the correlative 
nature of the study, which does not preclude causal contributions from possible 
self-selection factors, such as a predisposition for low striatal DA production 
that seduces people to use cannabis. It may also be suspected that significantly 
more nicotine smokers in the chronic cannabis condition might have 
contributed to the difference in the observed EBR between groups. However, 
not only did the critical effect survive the input of nicotine use as covariate but 
research also indicates that the long-term effect of nicotine on DA is facilitatory 
rather than inhibitory (Quik et al., 2006). This suggests that, if anything, the 
observed reduction in EBR provides a rather conservative estimate of the 
association between cannabis use and striatal DA levels. 
To conclude, the results of the present study point to less efficient 
striatal dopaminergic functioning in chronic cannabis users. This finding seems 
crucial in understanding the suspected psychotic effects of long-term cannabis 
use and throws some doubt on the claim that cannabis-induced psychosis 
results from the combination of increased striatal and reduced prefrontal DA 














indirect effect on DA implies caution in predictions of DA-related disorders due 
to chronic cannabis use. As a result of dopaminergic neurons not being 
impaired by cannabinoids, long-term consequences of cannabis exposure may 
be less severe than in the case of drugs directly damaging dopaminergic cells, 
as occurs with cocaine use (for a discussion, see: Colzato et al., 2008). More 
research is required in order to identify the neurophysiological and cognitive 
effects of continuous marijuana use, which are likely to be more subtle than 
those of other recreational drugs. 
Materials and Methods 
Participants 
Fifty-three healthy adults served as participants: 28 chronic cannabis 
users and 25 non-user controls. Participants received either course credit or 
financial reward. The sample was obtained from the city of Leiden using local 
advertisement, posts on community bulletin boards, and leaflets distributed in 
Leiden “coffee shops” (in which Dutch law permits selling/serving soft drugs to 
customers). Subjects were informed that they will participate in a study on the 
cognitive and neural effects of cannabis.  
Following Colzato and Hommel (2008), the inclusion criterion for 
cannabis users was a weekly consumption of at least four joints for a minimum 
of 2 years. The exclusion criteria were: (1) current or previous regular use of 
other drugs except for cannabis (regular use defined as having used a drug 
more than three times in a lifetime), (2) abuse of alcohol (more than 14 units 
per week), (3) history or presence of an Axis 1 psychiatric disorder (DSM-IV; 
assessed with the use of the Mini International Neuropsychiatric Interview; 
M.I.N.I. [Lecrubier et al., 1997]), (4) clinically significant medical disease, and 
(5) use of psychotropic medication. Non-user controls were required to meet the 
same criteria, with the exception that they could not report current or previous 
cannabis use. Additionally, participants were not permitted to consume 
caffeine, chocolate, or alcohol 12 hours before the experimental session, or to 
use nicotine 2 hours before the study. It was also not allowed to use cannabis 
on the day of study. However, cannabis use on the previous day was accepted in 
order to minimize the impact of possible withdrawal effects of addicted chronic 
users. Within the study sample, two participants were rescheduled for another 
day due to non-compliance with the consumption avoidance requirements. 




Three individuals were excluded from the group of chronic users because of 
meeting the criteria for a psychiatric disorder. 
Both groups were matched for age, gender, race (92% Caucasian, 8% 
Turkish), and IQ (measured by Raven’s Standard Progressive Matrices; SPM 
[23]). The demographic and cannabis use statistics are presented in Tables 1 
and 2, respectively. Additionally, in Table 1 the results of t-tests are presented 
to provide a comparison of demographic group characteristics. Written 
informed consent was acquired from all participants after the nature of the 
study had been explained to them. The protocol and compensation for 
participants were approved by the institutional review board (Leiden 
University, Institute for Psychological Research).  
 
Table 1 Demographic data. 
Standard deviation in parentheses; n.s.: non-significant difference; Race: C – Caucasian, 
T – Turkish; Raven IQ: measured by Raven’s Standard Progressive Matrices; Alcohol 
use: consumption of units per week; Nicotine use: S – smoker, NS – non-smoker. 
**p < 0.01. 
 
Table 2 Self-reported cannabis use. 
Standard deviation in parentheses; Monthly regular, monthly peak cannabis use and 








N (M : F) 25 (13 : 12) 25 (19 : 6) n.s. 
Age (years) 21.7 (3.8) 23.9 (4.4) n.s. 
Race 23 C : 2 T 23 C : 2 T n.s. 
Raven IQ 124.4 (5.6) 124.2 (7.6) n.s. 
Alcohol use 3.1 (2.4) 3.9 (2.8) n.s. 
Nicotine use 4 S : 21 NS 21 S : 4 NS ** 
Sample Mean (SD) 
Years of exposure 5.4 (4.4) 
Age of onset 18.4 (2.9) 
Monthly regular use 62.5 (45.7) 
Peak use in a month 131.8 (81.6) 














Procedure and Design 
Spontaneous EBR was recorded using a BioSemi ActiveTwo system 
(BioSemi Inc., Amsterdam, The Netherlands). The recording took place with 
two horizontal (one left, one right) and two vertical (one upper, one lower of 
right eye) Ag-AgCl electrodes. A vertical electrooculogram (EOG), which 
records the voltage difference between two electrodes placed above and below 
the left eye, was used to detect eye blinks. A horizontal EOG, which records the 
voltage difference between electrodes placed lateral to the external canthi, was 
used to measure horizontal eye movements in order to provide an online 
prevention of movement artifacts in the data. The EOG signals were digitized 
at 512 Hz. Data analysis was performed using Brain Vision Analyzer (Brain 
Products™ GmbH, Munich, Germany; 
http://www.brainproducts.com/products/analyzer/index_analyzer.html) with a 
high-pass filter of 1 Hz applied offline. Eye blinks were semi-automatically 
detected using the built-in Gratton and Coles (Gratton et al., 1983) algorithm. 
Recordings did not take place after 5 p.m. due to spontaneous EBR being stable 
during daytime, but increasing in the evening (around 8:30 p.m. [Barbato et al., 
2000]). Participants were comfortably sitting in front of a blank poster with a 
cross in the center, located about 1 m from the subject. Participants were alone 
in the room and asked to look at the cross in a relaxed state. The recording 
lasted 6 minutes. Individual EBR was calculated by dividing the total number 
of eye blinks during the 6-minute measurement interval by six. 
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Rationale Cannabis users often claim that cannabis has the potential to 
enhance their creativity. Research suggests that aspects of creative 
performance might be improved when intoxicated with cannabis; however, the 
evidence is not conclusive.  
Objective The aim of this study was to investigate the acute effects of 
cannabis on creativity. 
Methods We examined the effects of administering a low (5.5 mg THC) 
or high (22 mg THC) dose of vaporized cannabis vs. placebo on creativity tasks 
tapping into divergent (Alternate Uses Task) and convergent (Remote 
Associates Task) thinking, in a population of regular cannabis users. The study 
used a randomized, double-blind, between-groups design. 
Results Participants in the high dose group (n = 18) displayed 
significantly worse performance on the divergent thinking task than 
individuals in both the low dose (n = 18) and placebo (n = 18) groups did. 
Conclusions The findings suggest that cannabis with low potency does 
not have any impact on creativity while highly potent cannabis actually 
impairs divergent thinking. 
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Anecdotal evidence suggests that cannabis intoxication enhances 
human creativity. In line with that, Steve Jobs, an undeniably creative mind, 
once stated: “The best way I could describe the effect of the marijuana and 
hashish is that it would make me relaxed and creative". Other regular users 
claim that cannabis induces a state in which they experience unusual and 
original thoughts (Tart, 1970). In a more recent review, over 50% of users 
reported heightened creativity during cannabis intoxication (Green et al., 2003). 
This widespread perception of cannabis as a creativity-enhancer makes it 
important to verify whether cannabis actually induces these supposed effects. 
Delta-9-tetrahydrocannabinol (THC), the main psychoactive compound present 
in the Cannabis sativa plant, has been found to reduce inhibitory control 
(McDonald et al., 2003) and stimulate striatal dopamine (DA) release (Bossong 
et al., 2009; Kuepper et al., 2013). These features of THC intoxication, in turn, 
are expected to play a role in particular aspects of creative thinking (Akbari 
Chermahini et al., 2010; Hommel, 2012). On the other hand, THC has been 
linked to the emergence of psychotic symptoms due to acute administration 
(D’Souza et al., 2004), as well as in the long-term (Kuepper et al., 2010). As a 
result, the possible beneficial effects of using cannabis, if any, might not 
outweigh the potential risks associated with its abuse. 
The concept of creativity is not very well defined and there is no 
agreement on one particular measure of how to assess it. While some authors 
consider the concept to refer to the product of creative activities, others take it 
to reflect the personality of the product’s creator (for an overview, see: Runco, 
2007). To circumvent these difficulties, we restricted our analyses to two well-
established creative processes, and the respective classical assessment methods: 
divergent and convergent thinking (Guilford, 1967). Divergent thinking takes 
place when people try to find as many solutions to a loosely defined problem as 
possible—a process often referred to as “brainstorming”. It is often assessed by 
means of Guilford’s (1967) Alternate Uses Task (AUT), which requires 
individuals to generate as many as possible uses for a common household item 
(such as a pen or book) as they can think of (e.g., reading it, using it as a 
doorstop, etc.). In contrast, convergent thinking takes place when trying to find 
the one possible solution to a very well defined problem. This process is often 
assessed by means of Mednick’s (1962) Remote Associates Task (RAT), in 
which people are presented with three supposedly unrelated concepts (e.g., 
“time”, “hair”, “stretch”) and are requested to identify the one concept that can 




be related to all three of them (“long”). Research indicates that performance in 
AUT and RAT is not (strongly) correlated (Akbari Chermahini and Hommel, 
2010; Akbari Chermahini et al., 2012). Moreover, there is evidence that the two 
types of creative thinking are differently related to subcortical DA levels: while 
divergent thinking performance relates to markers of DA levels in the form of 
an inverted U-shape, convergent thinking performance displays a linear, 
negative correlation with DA markers (Akbari Chermahini and Hommel, 2010). 
In addition, this dissociation of human creativity seems to correspond to the 
Dual Pathway to Creativity model (De Dreu et al., 2008; Nijstad et al., 2010) 
suggesting that creative performance emerges from the balance between 
cognitive flexibility and cognitive persistence—two dissociable cognitive control 
functions (De Dreu et al., 2012).  
With regard to the neural effects of THC, the link between creative 
thinking and DA appears to be particularly interesting. Administration of THC 
has been shown to indirectly induce DA release in the striatum (Bossong et al., 
2009; Kuepper et al., 2013) and there is evidence that its chronic application 
can lead to dopaminergic hypoactivity in the long-term, especially if the onset 
of cannabis use is at a young age (Hoffman et al., 2003; Urban et al., 2012; 
Bloomfield et al., 2014). As divergent thinking performance is expected to be 
optimal with medium subcortical DA levels (Akbari Chermahini and Hommel, 
2010), one may suspect that THC can have a beneficial effect on this creative 
process, particularly in individuals with low dopaminergic functioning. This 
assumption is further supported by the fact that the reduction in inhibitory 
control, as observed in response to stimulation by pure THC (McDonald et al., 
2003) and cannabis (Ramaekers et al., 2006; Ramaekers et al., 2009), has been 
related to dopaminergic functioning as well (Mink, 1996). Reduced inhibitory 
control can be considered to reflect a cognitive control state with weak top-
down guidance. Such a state should affect convergent and divergent thinking 
differently (Hommel, 2012). As pointed out by Bogacz (2007), human decision-
making and the retrieval of possible alternatives can be considered a process 
that emerges from the interaction of top-down guidance and low-level 
competition between alternatives. If so, convergent thinking, with its many 
top-down constraints targeting one single solution, would seem to require a 
control state that provides strong top-down guidance and strong local 
competition. In contrast, divergent thinking, with its loosely defined problem 
and its many solutions, seems to require a control state that provides weak top-
down guidance and only little local competition (Hommel 2012). To the degree 














local competition, it might thus be expected to improve divergent thinking, 
interfere with convergent thinking, or both (Hommel, 2012; Colzato et al., 
2012). 
Unfortunately, the available research on the link between cannabis and 
creativity allows only for partial verification of these expectations. With respect 
to divergent thinking, one study showed that subjects intoxicated with joints 
(cannabis cigarettes) containing a low dose of THC (3 mg in total) displayed 
significantly enhanced performance on two divergent production tasks, 
compared to a group that received a higher THC dose (6 mg in total; Weckowicz 
et al., 1975). Curran et al. (2002) showed that, as compared to placebo, oral 
THC (7.5 and 15 mg) dose-dependently improved verbal fluency—an important 
aspect of divergent thinking (Guilford, 1967), at least as assessed by the AUT. 
Improved verbal fluency performance was also found in a naturalistic study 
that showed the beneficial effect of smoked cannabis (10% THC on average) on 
divergent thinking to be restricted to users low in trait creativity (i.e., 
individuals that obtained a low score on a self-assessment questionnaire about 
achievements in different creative domains; Schafer et al., 2012). In addition to 
fluency, cannabis administration (joints containing 19 mg of THC) has also 
been shown to increase the number of original responses on a test of associative 
processes, in comparison to placebo (Block et al., 1992). In contrast, 
Tinklenberg et al. (1978) did not observe any improvement in performance 
during the Torrance Tests of Creative Thinking (TTCT; Torrance, 1966), which 
is often assumed to tap into divergent thinking, after oral consumption of THC 
(a biscuit containing 0.3 mg/kg body weight of THC). Another study found 
decreased TTCT scores for fluency, flexibility, and elaboration after smoking a 
cannabis joint (containing 10 mg of THC) in regular cannabis users but not in 
first-time users (Bourassa and Vaugeois, 2001). In summary, the 
methodological differences between the various studies aside, many but not all 
findings suggest that THC may induce a cognitive control state with weak top-
down guidance, thus efficiently decreasing the competition between cognitive 
representations and enhancing divergent thinking (Hommel 2012; Colzato et 
al., 2012).  
For convergent thinking, the evidence is even more limited. Weckowicz 
et al. (1975) observed a trend towards less efficient convergent thinking tasks 
after smoking joints containing a low dose of THC (3 mg in total) or a higher 
dose (6 mg in total), in comparison to both a placebo and a pure control group. 
However, the same study also found impaired convergent thinking but only for 
the high dose condition. The most recent investigation found potentially 




detrimental effects of smoking cannabis (10% THC on average) on RAT 
performance in a group of cannabis users assumed to be high in trait creativity 
(Schafer et al., 2012). Although the naturalistic approach of this study makes it 
difficult to account for specific dose-related differences, the results of the 
research of both Schafer et al. (2012) and Weckowicz et al. (1975) suggest that 
THC can disrupt the process of searching and converging on a single solution to 
a problem.  
A number of the observed inconsistencies between studies might be due 
to differences with respect to THC dosage and method of administration, which, 
in turn, affects the bioavailability and the onset of action of the compound 
(Hazekamp et al., 2006). Moreover, an individual's history of cannabis use 
needs to be identified before cognitive changes in response to THC can be 
predicted. Administration of joints (containing up to 39 mg of THC) to regular 
cannabis users has been found to produce no accuracy impairments on a test 
battery assessing several cognitive functions (Hart et al., 2001) and, more 
specifically, on tasks related to episodic and working memory (Hart et al., 
2010). Furthermore, after smoking a cannabis joint (containing 500 µg/kg body 
weight THC), chronic users did not display any behavioral deficiencies on tasks 
assessing tracking performance and divided attention (Ramaekers et al., 2009), 
or changes in an event-related potential (ERP) reflecting early attentional 
processes (Theunissen et al., 2012), compared to infrequent users. In addition, 
regular cannabis users were shown to display reduced sensitivity to the 
psychotomimetic effects of THC (administered as an intravenous dose of up to 5 
mg; D’Souza et al., 2008). In contrast, inhibitory control has been found to be 
similarly impaired among both occasional and chronic users when intoxicated 
with cannabis (Ramaekers et al., 2009).  
Accordingly, since research points to reduced cannabinoid receptor type 
1 (CB1) density in the brains of regular cannabis users (Hirvonen et al., 2012), 
one may suspect that the tolerance of chronic users to some of the detrimental 
effects of THC is, to some extent, related to their dopaminergic functioning. 
Specifically, due to the concentration of CB1 receptors at gamma-aminobutyric 
acid (GABA) and glutamate neurons, CB1 receptor downregulation can 
influence the activity of these neurotransmitters (Hoffman et al., 2003). 
Because DA neurons are frequently co-localized with GABAergic and 
glutamatergic terminals, the dopaminergic deficiencies observed in chronic 
cannabis users may be explained by lasting, maladaptive modulation of DA by 
GABA and glutamate (Fattore et al., 2010; Fernández-Ruiz et al., 2010). If so, 














levels and divergent thinking performance (Akbari Chermahini and Hommel, 
2010) and the effect of THC on striatal DA release (Bossong et al., 2009; 
Kuepper et al., 2013), it may be expected that individuals with a relatively low 
level of dopaminergic functioning, such as regular cannabis users, are more 
likely to demonstrate enhanced performance on a divergent thinking task, 
provided that the THC dose is not excessively high. In contrast, in a population 
without long-term dopaminergic imbalances, such as healthy drug-naïve 
individuals, even a reasonably low dose of THC could stimulate DA production 
to a level that exceeds the threshold for optimal performance. In the case of 
convergent thinking performance, which is best with low subcortical DA levels 
(Akbari Chermahini and Hommel, 2010), it may be predicted that it will 
deteriorate in response to THC, irrespective of the dose and cannabis use 
history of the individual. 
In order to examine these possibilities, we investigated the effect of two 
different doses of vaporized cannabis (containing 5.5 or 22 mg of THC; see 
section Study drugs) and placebo on convergent and divergent thinking in a 
sample of chronic cannabis users, using a between-groups design. On the basis 
of the assumption that a low dose of cannabis can remove potential 
impairments caused by regular use (Weckowicz et al., 1975; Kelleher et al., 
2004), we expected that participants intoxicated with a low dose of cannabis 
should display higher scores on a divergent thinking task than those receiving 
placebo would. Conversely, we predicted impairment of performance in the 
high dose condition, in contrast to the low dose and placebo conditions. In the 
case of convergent thinking, we expected that both doses of cannabis should 
impair this process, compared to placebo. In addition, since divergent thinking 
performance has been found to be related to an individual’s mood (Zenasni and 
Lubart, 2011), we assessed perceived mood as a possible modulating factor.  
Materials and Methods 
The current study was part of a larger study which involved additional 




Power analysis was performed to assess the approximate number of 
subjects required for detecting medium (d = 0.5) or large effect sizes (d = 0.8). 




Consequently, with an expected sample size of 60, three conditions, and a set 
alpha of 0.05, the power to detect main effects with a medium or large effect 
size for a between-groups ANOVA is 0.679 and 0.979, respectively. Calculations 
were made using the analysis program fpower (Friendly 2014). 
Fifty-nine healthy regular cannabis users (52 males and seven females) 
participated in the study in exchange for a small financial compensation. 
Subjects were recruited through advertisements on the internet, on community 
bulletin boards, and in coffee shops (outlets in which Dutch law permits the 
sale of small quantities of cannabis to consumers) and by word of mouth. 
Detailed demographic and substance use information is presented in Table 1. 
Written informed consent was obtained from all participants after a complete 
explanation of the nature of the study. The study was approved by the Medical 
Ethics Committee of the Leiden University Medical Center.  
The participants were randomly assigned to one out of three 
experimental conditions: placebo, 5.5 mg or 22 mg of THC. The groups were 
comparable in terms of age, substance use characteristics, and IQ test score. 
All subjects were required to be regular users (use cannabis at least four times 
a week, for a minimum of 2 years) and to be native Dutch speakers. The 
exclusion criteria were: (1) history or presence of an axis I psychiatric disorder 
(DSM-IV; assessed with the use of the Mini International Neuropsychiatric 
Interview; M.I.N.I: Lecrubier et al., 1997); (2) clinically significant medical 
disease; (3) use of psychotropic medication; (4) current or previous regular use 
of other drugs except cannabis (regular use defined as having used a drug more 
than four times in a lifetime); (5) abuse of alcohol (more than 14 units a week). 
Compliance with the inclusion and exclusion criteria was assessed by means of 
self-report. Additionally, subjects were asked to refrain from caffeine, chocolate, 
and alcohol 12 hours before the experimental session and not to use nicotine 2 
hours before the study. It was also not allowed to use cannabis within 2 days 
before the experiment. Participants’ compliance with these criteria was 
evaluated by means of a personal interview and the use of a saliva drug test, 
which detected the recent use of cannabis, morphine, or cocaine (Oral-View™ 
Saliva Multi-Drug of Abuse Test; Alfa Scientific Designs Inc., Poway, CA, 
U.S.A.).  
From the initial sample of 59 subjects, two male participants withdrew 
from the study before completing the two creativity tasks—one stated personal 
issues, while the other did not provide any explanation. Another subject 
experienced anxiety before cannabis administration and had to abort the 














participant reported anxiety, combined with fatigue and nausea, which 
prevented him from completing the tasks. Moreover, one female subject was 
excluded from the analysis due to lack of compliance to task requirements (i.e., 
she refused to complete the tasks due to not liking their nature). This left 54 
subjects for the final analysis (48 males and six females), except for the 
convergent thinking task (RAT). In this case, one male participant (in the 22 
mg THC condition) requested to abort the study due to personal reasons before 




The active drug substance consisted of the dried, milled, and 
homogenized flowers of the plant Cannabis sativa (variety ‘Bedrocan’®; 19% 
THC). It was obtained from Bedrocan BV (Veendam, The Netherlands) where it 
was cultivated under standardized conditions according to the requirements of 
Good Agricultural Practice (GAP). The placebo (variety ‘Bedrocan’®; <0.5% 
THC) used in the study had a moisture content and terpenoid profile (providing 
the typical smell and taste of cannabis) identical to the active drug. Study 
medication was prepared by ACE Pharmaceuticals BV (Zeewolde, The 
Netherlands). For each individual dose, exact amounts of active cannabis and 
placebo were mixed so that each dose was equal to 250 mg total weight but 
with varying concentrations of THC (placebo/5.5 mg/22 mg THC). Study 
medication was stored in a refrigerator (2–8°C) in triple-layer laminated foil 
pouches (Lamigrip). Shelf life stability under these conditions was determined 
to be at least 1 year. 
On the study day, each subject received a randomized single dose of 
cannabis by means of a Volcano® vaporizer (Storz&Bickel GmbH, Tüttlingen, 
Germany)—a reliable and safe method of intrapulmonary administration of 
THC (Hazekamp et al., 2006; Zuurman et al., 2008). Cannabis was vaporized at 
a temperature of 230°C into a standard Volcano balloon as supplied with the 
vaporizer. For blinding purposes, the Volcano balloon was covered with a non-
transparent plastic bag so that no differences in the density of the vapor were 
visible between dosages. 
When administering THC by means of vaporizing, it should be taken 
into account that only part of the dose present in the plant material is 
vaporized into the balloon (Hazekamp et al., 2006), and that a portion of the 
THC inhaled from the balloon is not absorbed by the lungs but is exhaled again 
(Zuurman et al., 2008). Therefore, in order to achieve an absorbed dose of 




approx. 2- and 8 mg THC, we loaded the Volcano vaporizer with 5.5 and 22 mg 
of THC, respectively. Moreover, since the THC delivery of the Volcano 
vaporizer and cannabis joints is comparable (Abrams et al., 2007), the loaded 
vs. absorbed dose distinction can be applied to smoked cannabis as well.  
During administration, subjects were instructed to inhale deeply and 
hold their breath for 10 seconds after each inhalation. They were not allowed to 
speak during the inhalation period and were required to empty the balloon 
within 5 minutes. Subjects had the opportunity to practice the inhalation 
procedure using an empty balloon before cannabis administration. 
 
Shortened Raven's Standard Progressive Matrices (SPM; measure of 
intelligence) 
Individual IQ test scores were determined by means of a reasoning-
based intelligence test (Raven et al., 1988). Each item of this test consists of a 
pattern or sequence of a diagrammatic puzzle with one piece missing, the task 
being to complete the pattern or sequence by choosing the correct missing piece 
from a list of options. The items get more difficult as the test taker proceeds 
through the test. The SPM test assesses the individual's ability to create 
perceptual relations and to reason by analogy independent of language and 
formal schooling. The version of the test used in the study consisted of 14 items.  
 
Alternate Uses Task (AUT; divergent thinking) 
In this task (Guilford, 1967) participants were asked to list as many 
possible uses for two common household items (i.e., pen, shoe) as they could. 
The scoring had four components: Fluency (the total of all responses); 
Flexibility (the number of different categories used; e.g., "household uses"); 
Originality (where each response was compared to the responses from the other 
subjects, responses given by only 5% of the participants being counted as 
unusual [1 point] and responses given by only 1% as unique [2 points]); and 
Elaboration (referring to the amount of detail; e.g., while a book used as “a 
doorstop” would count 0, “a doorstop to prevent a door slamming shut in a 
strong wind” would count 2: 1 point for explanation of door slamming and 1 
point for additional detail about the wind). Of these four criteria, the 
component flexibility has been found to be the theoretically most transparent 

















Remote Associates Task (RAT; convergent thinking) 
In this task (developed by Mednick [1962]), participants were presented 
with three unrelated words (e.g., time, hair and stretch) and asked to find a 
common associate (long). The test consisted of 14 items, which were taken from 
Akbari Chermahini et al.’s (2012) Dutch version of the RAT.  
 
Affect grid (subjective measure of mood) 
As in Colzato et al. (2013), the current mood of participants was 
assessed by means of a 9 × 9, Pleasure × Arousal grid (Russell et al., 1989).  
 
Visual analogue scales (VAS; subjective measure of drug effects)  
The subjective effects of cannabis were assessed by means of three 
scales (horizontal 100-mm lines, the left pole labeled “not at all” and the right 
“extremely”) referring to “(feeling) High”, “Good drug effect”, and “Bad drug 
effect”. Participants were to mark a point at the continuous line to indicate 
their experience.  
 
Design and procedure 
The study used a randomized, double-blind, placebo-controlled, 
between-groups (placebo vs. 5.5 mg vs. 22 mg THC) design. All participants 
were tested individually and the order of the two creativity tasks—AUT and 
RAT—was counterbalanced. Upon arrival, the subjects were asked to complete 
the SPM test within 10 minutes. Afterwards, the study drug was administered. 
Six minutes after cannabis administration, participants were required to 
indicate the subjective effects of the drugs by means of the VAS. This 
assessment of the effects of the drugs was then repeated twice—before and 
after the completion of the two creativity tasks (35 and 60 minutes after 
administration). Participants were provided with both the AUT and RAT in 
printed form (in the time window between 35 and 60 minutes after 
administration) and had 10 minutes to complete each task. In addition, in 
order to evaluate the subjective perception of mood, subjects were required to 
rate their mood on the Affect grid after the completion of each creativity task 
(at 48 and 60 minutes after administration). 
 
Statistical analysis 
Scores from mood assessments and VAS, together with the five 
measures from the two creativity tasks (fluency, flexibility, originality, and 
elaboration scores from the AUT; the number of correct items from the RAT) 




were calculated for each subject. The results of the AUT were rated by two 
independent readers, blinded to the conditions (Cronbach’s alpha = 1.00 
[fluency]; 0.87 [flexibility]; 0.94 [originality]; 0.9 [elaboration]). The final scores 
were the means of both ratings. All measures were analyzed separately. In the 
case of the AUT, RAT, and IQ test scores, age, and substance use data, 
between-groups ANOVAs were run with condition (placebo vs. 5.5 mg vs. 22 mg 
THC) as between-groups factor. Data regarding sex was analyzed with the use 
of a Pearson's chi-squared test. Mood and VAS scores were analyzed by means 
of repeated-measures ANOVAs with time after cannabis administration (48 vs. 
60 minutes for mood; 6 vs. 35 vs. 60 minutes for VAS) as a within-subjects 
factor and condition as a between-groups factor. Post-hoc multiple comparison 
t-tests were applied with Bonferroni correction. A significance level of p < 0.05 
was adopted for all tests.  
Results 
Demographic and substance use data 
No significant main effects of condition were found in the case of age 
(F(2, 51) = 0.74, p = 0.482), IQ test score (F(2, 51) = 0.159, p = 0.854), monthly 
cannabis use (F(2, 51) = 0.453, p = 0.639), years of cannabis exposure (F(2, 51) 
= 1.433, p = 0.248), monthly alcohol use (F(2, 51) = 0.855, p = 0.431), years of 
alcohol exposure (F(2, 51) = 3.027, p = 0.057), monthly nicotine use (F(2, 51) = 
1.231, p = 0.3), and years of nicotine exposure (F(2, 51) = 0.383, p = 0.684). 
However, the experimental conditions significantly differed by sex (χ²(2, N = 54) 
= 7.875, p = 0.019); see Table 1. 
 
Creativity tasks 
Overall task performance in the AUT and RAT was comparable to that 
in studies without pharmacological interventions (e.g., Akbari Chermahini and 
Hommel 2010); see Figure 1 and Table 2. 
 
Divergent thinking 
Significant main effects of condition were found on fluency (F(2, 51) = 
7.378, p = 0.002), flexibility (F(2, 51) = 7.708, p = 0.001), and originality (F(2, 51) 
= 8.952, p < 0.001), but not on elaboration (p > 0.05). 
As expected, post-hoc multiple comparisons revealed that participants 














the participants in the placebo and 5.5 mg THC groups, respectively, for 
fluency (t(34) = 3.072, p = 0.01; t(34) = 3.582, p = 0.003), flexibility (t(34) = 
3.061, p = 0.011; t(34) = 3.367, p = 0.002) and originality (t(34) = 2.584, p = 
0.045; t(34) = 4.021, p < 0.001). However, contrary to expectations, subjects in 
the 5.5 mg THC condition did not display any significant increases from those 
receiving placebo, on any of the AUT components (p > 0.05). 
Moreover, in order to test whether sex differences had an impact on the 
observed results and match the groups for sex, we repeated the analysis after 
the exclusion of all female subjects. Significant main effects were retained for 
fluency (F(2, 45) = 5.774, p = 0.006), flexibility (F(2, 45) = 6.325, p = 0.004), and 
originality (F(2, 45) = 7.641, p = 0.001). 
 
Convergent thinking 
Contrary to expectations, there was no main effect of condition on the 
number of correct items from the RAT (p > 0.05).  
 
  




Table 1 Demographic and substance use data for each experimental group. 
 Placebo 5.5 mg THC 22 mg THC 
Significance 
level 
N (Male : Female) 
 
18 (18 : 0) 18 (17 : 1) 18 (13 : 5) p = 0.019 
Age 
 
21.1 (2.4) 21.1 (2.1) 22 (2.5) n.s. 
IQ test score 
 




42.8 (31.3) 51.3 (52.6) 39.3 (27.8) n.s. 
Years of cannabis 
exposure 
 




26.2 (17.8) 23.7 (19.8) 18.8 (13.5) n.s. 
Years of alcohol 
exposure 
 










Years of nicotine 
exposure 
 
4.6 (3.8) 3.5 (4.2) 4.3 (4) n.s. 
Standard deviations in parentheses; n.s.: non-significant difference; Age: reported in 
years; IQ test score: measured by a shortened version of Raven’s Standard Progressive 
Matrices; Monthly cannabis use: consumption of cannabis cigarettes (joints); Monthly 















Table 2 Means, SD, and ANOVA results for the four components of the 
Alternate Uses Task (AUT: fluency, flexibility, originality, elaboration), and the 







F p η2p MSE 









































0.116 0.891 0.005 8.904 
*p < 0.05 (significant difference between 5.5- and 22 mg THC, and between placebo and 
22 mg THC).  
 
  




Figure 1 Bar graphs showing mean scores for the four components of the 
Alternate Uses Task (AUT: fluency, flexibility, originality, elaboration) for each 
experimental group. The symbol (*) indicates a significant (p < 0.05) difference 
between the 5.5 mg and 22 mg THC conditions, and between the placebo and 
22 mg THC conditions. Error bars represent SE of the mean. 
 
 
Subjective measures of drug effects and mood 
Drug effects 
Overall, only the rating of “high” showed a main effect of time after 
cannabis administration (with Huynh-Feldt correction; F(1.862, 93.109) = 
15.777, p < 0.001). However, significant main effects of condition were found on 
all three scores: “high” (F(2, 50) = 11.656, p < 0.001), “good drug effect” (F(2, 50) 
= 8.701, p = 0.001), and “bad drug effect” (F(2, 50) = 6.507, p = 0.003). There 
were no significant interaction effects (p > 0.05). 
Post-hoc multiple comparisons revealed that subjects in the placebo 
condition showed significantly lower ratings of “high” than the 5.5 mg (t(34) = 
2.95, p = 0.006) and 22 mg THC groups (t(34) = 4.49, p < 0.001) did; see figure 2. 
Moreover, the ratings of “good drug effect” in the placebo condition were 
significantly lower than those in the 5.5 mg (t(34) = 3.535, p < 0.001) and 22 mg 














and “good drug effect”, no significant differences were found between the scores 
in the 5.5 mg and 22 mg THC groups (p > 0.05). Conversely, regarding the 
ratings of “bad drug effect”, participants in the 22 mg THC condition 
demonstrated significantly increased scores from those in the placebo (t(34) = 
3.48, p = 0.006) and 5.5 mg THC groups (t(34) = 3.141, p = 0.012); see figure 4. 
In addition, the ratings of “bad drug effect” did not significantly differ between 
the placebo and 5.5 mg THC conditions (p > 0.05).  
 
Mood 
There were no main effects of time after cannabis administration on the 
ratings of pleasure or arousal (p > 0.05). Moreover, mood ratings in the placebo 
(6.3 vs. 6.2 for pleasure; 5.1 vs. 5 for arousal), 5.5 mg (7.1 vs. 7 for pleasure; 5.5 
vs. 5.2 for arousal), and 22 mg THC (6.1 vs. 6.4 for pleasure; 4.8 vs. 4.7 for 
arousal) conditions did not show significant main effects of condition on 








Figure 2 Mean subjective high (rated as a percentage) experienced in each 
experimental group as a function of time after cannabis administration. 
Symbols indicate a significant (p < 0.01) difference between the 22 mg THC and 
placebo conditions (*), and between the 5.5 mg THC and placebo conditions (**). 
Error bars represent SE of the mean. 
Figure 3 Mean subjective good drug effect (rated as a percentage) experienced 
in each experimental group as a function of time after cannabis administration. 
Symbols indicate a significant (p < 0.05) difference between the 22 mg THC and 
placebo conditions (*), and between the 5.5 mg THC and placebo conditions (**). 














Figure 4 Mean subjective bad drug effect (rated as a percentage) experienced in 
each experimental group as a function of time after cannabis administration. 
Symbols indicate a significant (p < 0.05) difference between the placebo and 22 
mg THC conditions (*), and between the 5.5 mg and 22 mg THC conditions (**). 
Error bars represent SE of the mean. 
Discussion 
Our findings demonstrate that a high dose of vaporized cannabis (22 
mg THC) impairs divergent thinking in regular cannabis users, in comparison 
to a low dose (5.5 mg THC) and placebo cannabis preparation. This is reflected 
in the decreased scores for fluency, flexibility, and originality of responses of 
participants in the high dose condition. However, contrary to expectations, a 
low dose of cannabis did not enhance divergent thinking in chronic cannabis 
users: individuals in the low dose group did not significantly outperform 
subjects in the placebo group on any of the components of the AUT. Moreover, 
convergent thinking appears to be unaffected by either a low or high dose of 
cannabis, as condition had no impact on the numbers of correct RAT items.  
Although the conclusions are limited by a between-groups design, the 
finding that administration of a high, but not low, dose of cannabis impairs 
divergent thinking performance of regular cannabis users may suggest that DA 
release in the striata of participants in the high dose condition (Bossong et al., 




2009; Kuepper et al., 2013) exceeded the threshold for optimal performance 
(Akbari Chermahini and Hommel, 2010). This is in line with neuroscientific 
considerations that point to a homeostatic function of DA in regulating the 
balance between opposing cognitive control states—flexibility and stability 
(Cools et al., 2009; Cools and D'Esposito, 2011). Flexibility refers to the ability 
to effectively switch between cognitive representations for the purpose of 
choosing the best alternatives, while the function of stability is to promote 
constancy of representations in spite of interference (Cools and D'Esposito, 
2011). Consequently, keeping in mind the effect of cannabis on inhibition 
(Ramaekers et al., 2006; Ramaekers et al., 2009), it is safe to assume that 
individuals in the high dose condition experienced a reduction in inhibitory 
control after cannabis administration. Although this should promote a control 
state with weak top-down guidance allowing for flexible updating of 
information (Hommel, 2012; Colzato et al., 2012), supra-optimal levels of DA in 
the striatum have been found to stimulate flexibility to the point that it 
surpasses the threshold for optimal performance, inducing distractibility as a 
result (see: Cools and D'Esposito, 2011). Accordingly, it is possible that the 
observed impairment of divergent thinking in the high dose condition was the 
result of this process. Presumably, induction of a control state with weak top-
down guidance is a necessary, but not sufficient, prerequisite for enhanced 
divergent thinking performance. Conversely, excessively potent cannabis may 
disturb the delicate balance between stability and flexibility by stimulating 
flexibility to its extreme, hence impairing divergent thinking. 
In addition, from a more motivational perspective, it is possible that a 
high dose of cannabis induces the phenomenon of "ego-depletion" (i.e., exhausts 
the limited cognitive resources and motivation required for cognitive control 
operations; Baumeister et al., 1998; Inzlicht and Schmeichel, 2012). This seems 
probable taking into account the observation that participants in the high dose 
condition experienced more intense unpleasant subjective effects of cannabis 
than those in the low dose and placebo groups. In line with that, research 
points to anxiety, paranoia, delusions, and mental disorganization as frequent 
adverse effects of cannabis intoxication (Green et al., 2003; D’Souza et al., 
2004). Therefore, the various undesirable forms of distraction induced by 
cannabis could have drained the control resources of individuals in the high 
dose condition. In other words, it is possible that the need to exert self-control 
over the adverse effects of cannabis leads to a reduction in motivation and 
available cognitive resources required for subsequent optimal divergent 














In the low dose group, the lack of enhancement of divergent thinking 
does not provide support for the idea that a low dose of cannabis can eliminate 
cognitive impairments caused by regular use (Weckowicz et al., 1975; Kelleher 
et al., 2004). Nevertheless, since the performance of subjects in the low dose 
and placebo groups was comparable in the case of the AUT, it may be assumed 
that the lack of cannabis-induced cognitive deterioration in the low dose 
condition was indicative of the tolerance of regular cannabis users to the effects 
of the drug (Hart et al., 2001; Ramaekers et al., 2009; Hart et al., 2010; 
Theunissen et al., 2012). Furthermore, it is possible that the similar level of 
performance of both groups reflects their maximal potential for divergent 
thinking. Research indicates that placebo effects are able to stimulate 
subcortical DA release (Scott et al., 2007; Scott et al., 2008). Possibly, 
administration of a low dose of cannabis resulted in a dopaminergic response 
comparable to that in the placebo condition (Bossong et al., 2009; Kuepper et 
al., 2013). This seems plausible considering the fact that the placebo cannabis 
preparation used in the study was identical in terms of smell and taste to 
actual cannabis. As such, it had more potential to produce a placebo effect. In 
addition, the minimal amount of THC present in the placebo might have also 
affected DA release to some extent. Consequently, the subcortical DA levels of 
individuals in both the low dose and placebo conditions could have been within 
the range for optimal divergent thinking performance (Akbari Chermahini and 
Hommel, 2010).  
 
Limitations 
Although the most recent investigation into the link between cannabis 
and convergent thinking suggested a potentially detrimental effect of cannabis 
intoxication on this process (Schafer et al., 2012), our study failed to detect any 
impact on RAT performance. Perhaps our version of the task with 14 items was 
not sensitive enough to identify potential cannabis-induced impairments. 
Moreover, an important limitation is the between-groups design of the study. 
Consequently, it is possible that particular characteristics of the subject sample 
could have altered the effects of the drug. Specifically, the difference in sex 
between the conditions seems to be a likely candidate in this regard (Crane et 
al., 2013). In addition, research points to genetic predispositions like 
polymorphism of the CB1 receptor gene (Ho et al., 2011; Stadelman et al., 2011), 
or the catechol-O-methyltransferase (COMT) gene (Schulz et al., 2012) as other 
factors which might modulate the cognitive effects of cannabis intoxication. 




Another issue is related to the causal relation between the observed 
results and THC. In spite of the fact that application of cannabis, instead of 
pure THC, provides the benefit of a higher ecological validity of the study, the 
use of plant material could have influenced the findings. Specifically, 
terpenoids, which are the compounds responsible for the characteristic smell 
and taste of cannabis, have been shown to interact with cannabinoids to 
produce various synergistic effects (see: Russo, 2011). However, even if that 
was the case in our experiment, the terpenoid profile was comparable between 
the different doses, including the placebo cannabis preparation. Consequently, 
any potential terpenoid–cannabinoid interactions were controlled for. 
Unfortunately, the study lacked a measurement of THC blood plasma levels, 
which would allow for evaluating the relation between THC in the bloodstream 
and task performance. Furthermore, since the number of inhalations from the 
Volcano balloon and the duration of inhalations were not standardized, it is 
likely that this resulted in large differences in absorbed THC between subjects. 
In addition, the saliva test used in our experiment provided only an estimate of 
recent use. Possibly, the compliance of subjects with no-consumption criteria 
should instead be verified by examination of the urinary levels of THC 
metabolites (11-COOH-THC), which is capable of detecting intoxication over a 
longer period of time. Moreover, the lack of testing for alcohol intoxication can 
be considered another limitation in evaluating the compliance of participants 
with no-consumption criteria. 
 
Conclusion 
The findings indicate that administration of cannabis with a high THC 
content to regular cannabis users is detrimental for divergent thinking, while 
less potent cannabis does not seem to enhance this important component of 
creativity. The available evidence allows only for a speculation about the 
presence of these effects in a group of drug-naïve individuals, or occasional 
cannabis users. In any case, it can be claimed that the phenomenological 
experience of a person intoxicated with cannabis might not necessarily reflect 
his or her actual performance. In particular, the frequently reported feeling of 
heightened creativity could be an illusion. In other words, smoking a joint may 
not be the best choice when in need of breaking "writer's block", or overcoming 
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Cannabis has been suggested to impair the capacity to recognize 
discrepancies between expected and executed actions. However, there is a lack 
of conclusive evidence regarding the acute impact of cannabis on the neural 
correlates of error monitoring. In order to contribute to the available knowledge, 
we used a randomized, double-blind, between-groups design to investigate the 
impact of administration of a low (5.5 mg delta-9-tetrahydrocannabinol [THC]) 
or high (22 mg THC) dose of vaporized cannabis vs. placebo on the amplitudes 
of the error-related negativity (ERN) and error positivity (Pe) in the context of 
the Flanker task, in a group of frequent cannabis users (required to use 
cannabis minimally four times a week, for at least 2 years). Subjects in the 
high dose group (n = 18) demonstrated a significantly diminished ERN in 
comparison to the placebo condition (n = 19), whereas a reduced Pe amplitude 
was observed in both the high and low dose (n = 18) conditions, as compared to 
placebo. The results suggest that a high dose of cannabis may affect the neural 
correlates of both the conscious (late) and the initial automatic processes 
involved in error monitoring, while a low dose of cannabis might impact only 
the conscious (late) processing of errors. 
 
Keywords: cannabis, THC, error monitoring, error-related negativity, error 
positivity 
  














Cannabis sativa is a plant which contains over 70 active constituents 
named cannabinoids (Schoedel and Harrison, 2012). Delta-9-
tetrahydrocannabinol (THC), the main psychoactive cannabinoid present in the 
plant, has been found to evoke most of the subjective effects of marijuana 
(Grotenhermen, 2003). Around 20% of young people worldwide abuse the 
psychoactive effects of THC and other cannabinoids through regular use of the 
cannabis plant (Moore et al., 2007). This makes it important to understand 
whether and how cannabis intoxication affects human information processing. 
In the present study, we investigated the impact of cannabis on the monitoring 
of action errors, that is, on the recognition of discrepancies between expected 
and executed actions. To date, only one study has addressed the acute effects of 
cannabis on error monitoring (Spronk et al., 2011), while three other studies 
have considered the after-effects of chronic cannabis use (Hester et al., 2009; 
Harding et al., 2012; Fridberg et al., 2013). The present study aimed to 
contribute to the available knowledge by means of a between-subjects, double-
blind, placebo-controlled design that compared the effects of two different doses 
of THC, in the form of herbal cannabis, on event-related potentials (ERPs) in a 
population of frequent cannabis users. 
The monitoring of errors is an important element of cognitive control. It 
contributes to the fine-tuning of top-down control over information processing 
by signaling insufficient degrees of control to goal-related control systems 
(Botvinick et al., 2001). Interestingly for our purposes, the monitoring of errors 
can be assessed by means of electroencephalography (EEG). Specifically, a 
negative deflection can be noticed in the event-related potential (ERP) at 
around 50–100 ms after a person commits an error in a task—the so-called 
error-related negativity (Ne: Falkenstein et al., 1990; ERN: Gehring et al., 
1993). The ERN has been established as a valid measure of error monitoring 
(Holroyd and Coles, 2002; Yeung et al., 2004; Ullsperger et al., 2014) and 
imaging research has identified the anterior cingulate cortex (ACC) as the most 
likely brain area responsible for generating the potential (Herrmann et al., 
2004; Stemmer et al., 2004; Debener et al., 2005). 
The ACC, aside of being an important relay station for cognitive control 
processes, is also a brain region that integrates cognitive and emotional 
information (Bush et al., 2000; Botvinick et al., 2001; Paus, 2001; Shackman et 
al., 2011). In line with that, it has been proposed that its activity is directly 
related to that of the mesencephalic dopamine (DA) system, by which the error 
signal is conveyed to the ACC (Holroyd and Coles, 2002). Considering the 




neural effects of THC, the connection between error monitoring and DA seems 
to be especially interesting. Application of THC has been identified to indirectly 
stimulate DA production in the striatum (Bossong et al., 2009; Kuepper et al., 
2013). Moreover, research indicates that chronic THC administration can 
result in long-term dopaminergic hypoactivity, particularly if the onset of 
cannabis use is at an early age (Hoffman et al., 2003; Urban et al., 2012; 
Bloomfield et al., 2014). Consequently, since error monitoring is assumed to 
depend on phasic changes in the tonic activity of the mesencephalic 
dopaminergic system (Holroyd and Coles, 2002), it seems likely that cannabis 
has an effect on this process. 
In line with this DA account of the ERN, the only up-to-date study 
investigating the impact of acute administration of THC on error monitoring 
showed a reduced ERN in response to this cannabinoid (16 mg in total), 
compared to placebo (Spronk et al., 2011). Moreover, cannabis has been 
identified to alter the neural correlates of error monitoring in the long-term. 
Specifically, an ERP study showed an increased amplitude of the error 
positivity (Pe; i.e., a positive component which can be observed in the time 
interval between 200 and 500 ms after an erroneous response; Falkenstein et 
al., 2000) in a group of chronic cannabis users, compared to that in non-users 
(Fridberg et al., 2013). Although the Pe has not been studied as well as the 
ERN (Fridberg et al., 2013), evidence suggests that it represents a later stage 
of error processing, independent of the ERN (Falkenstein et al., 2000), and is 
linked to the conscious awareness of errors (Nieuwenhuis et al., 2001; Murphy 
et al., 2012). In the case of neuroimaging research, a decreased blood-oxygen 
level dependent (BOLD) signal to errors has been observed in the ACC and 
right insula of regular cannabis users, as compared to that in non-user controls 
(Hester et al., 2009). Furthermore, heightened demand for cognitive control has 
been associated with increased connectivity between the prefrontal (PFC) and 
occipitoparietal cortex (OP) in the brains of chronic users (Harding et al., 2012). 
Accordingly, the combined results of the different studies suggest that chronic 
cannabis use leads to both impaired error monitoring in these individuals and 
to possible development of a mechanism to compensate for the deterioration of 
the process of identification of errors in information processing. Specifically, 
compared to non-user controls, cannabis users recruit additional cortical 
activity in areas associated with cognitive control, or other brain regions not 
associated with this process (Tapert et al., 2007; Hester et al., 2009). In the 
case of the acute effects of cannabis, based on the single study by Spronk et al. 













(2011), it can be assumed that error monitoring is impaired as a result of 
administration of THC.  
Due to the scarcity of the data on this topic, it would be especially 
interesting to take into account different factors which can modulate the effect 
of administering THC on error monitoring. One such factor is the link between 
chronic and acute cannabis use. Specifically, the history of cannabis use of an 
individual has been shown to modulate the effects of cannabis intoxication. 
Chronic cannabis users smoking cannabis cigarettes (joints; containing 
maximally 39 mg of THC) have been shown to demonstrate no accuracy 
deficiencies on a number of tasks tapping into different cognitive functions 
(Hart et al., 2001) and, in particular, on episodic and working memory tests 
(Hart et al., 2010). In addition, compared to infrequent users, chronic users did 
not display any behavioral impairments on tasks evaluating tracking error and 
divided attention (Ramaekers et al., 2009) or changes in an ERP indicative of 
early attentional processes (Theunissen et al., 2012), following smoking of a 
cannabis joint (with 500 μg/kg body weight THC). Conversely, inhibitory 
control has been identified to be equally diminished among both chronic and 
occasional users due to cannabis administration (Ramaekers et al., 2009). In 
summary, it makes sense to assume that this specific cannabinoid tolerance of 
regular users is not limited to particular cognitive functions, but extends to the 
development of a compensatory mechanism for deficiencies in cognitive control 
(Harding et al., 2012; Fridberg et al., 2013). However, this compensation 
appears to have its limits due to impaired inhibitory control—a critical element 
in the top-down control over information processing (Botvinick et al., 2001).  
Moreover, both the neurocognitive and the subjective effects of 
cannabis have been demonstrated to be highly dependent on the specific dose of 
THC administered (Hart et al., 2001; Ramaekers et al., 2006; Hart et al., 2010; 
D’Souza et al., 2012; Hunault et al., 2014). Consequently, when investigating 
the effect of cannabis on error monitoring, different results may be expected 
depending on the combination of the dose and history of cannabis use of the 
studied sample. For instance, a relatively low dose of THC may not produce 
visible changes in the error monitoring system of chronic cannabis users, while 
the compensatory mechanism may not be sufficient to prevent the impairments 
caused by a relatively high dose of THC. 
In order to test these speculations, we examined the impact of two 
different doses of vaporized cannabis (5.5 mg or 22 mg of THC; see Study drugs 
section) and placebo on the amplitudes of the ERN and Pe. Moreover, we 
recruited only frequent cannabis users in our sample due to their partial 




tolerance to the impairing effects of cannabis (Hart et al., 2001; Kelleher et al., 
2004; D’Souza et al., 2008; Ramaekers et al., 2009; Hart et al., 2010; 
Theunissen et al., 2012). Accordingly, based on the characteristics of the 
studied sample and on the reported effects of a relatively high dose of THC on 
the ERN (16 mg in total; Spronk et al., 2011), we expected to observe a 
decreased ERN amplitude following administration of the high, but not low 
cannabis dose or placebo. Since no studies have investigated the acute effects of 
cannabis on the Pe, we could only speculate that it would be affected in a 
similar manner to the ERN. The ERN and Pe were assessed in the context of a 
modified version of the Flanker task (Eriksen and Eriksen, 1974). Since 
administration of cannabis to regular users does not usually lead to overt error 
impairments (Hart et al., 2001; Ramaekers et al., 2009; Hart et al., 2010), we 
did not expect to observe any effects at the behavioral level.  
Experimental procedures 
The current research was part of a larger study which included other 
tasks and measurements. 
 
Participants 
The program fpower (Friendly, 2014) was used to estimate the 
approximate number of participants needed for detecting medium (d = 0.5) or 
large effect sizes (d = 0.8). With an estimated sample size of 60, three 
conditions, and a set alpha of 0.05, the power to detect main effects with a 
medium or large effect size for a between-groups ANOVA was estimated at 
0.679 and 0.979, respectively. 
Sixty-one healthy frequent cannabis users (53 males and eight females) 
took part for a small financial compensation. Participants were recruited 
through advertisements on the internet, on community bulletin boards, and in 
coffee shops (outlets in which the sale of minor quantities of cannabis to 
consumers is allowed by Dutch law), and by word of mouth. Specific 
demographic and substance use information is displayed in Table 1. Written 
informed consent was obtained from all subjects after a complete explanation of 
the nature of the research. The study was approved by the Medical Ethics 
Committee of the Leiden University Medical Center.  
The subjects were assigned at random to one out of three experimental 
groups: placebo, 5.5 mg, or 22 mg THC. The conditions were comparable with 













regard to sex, age, IQ test score, and substance use characteristics, except for 
years of alcohol exposure. All participants were requested to be frequent users 
(use cannabis minimally four times a week, for at least 2 years) and to be 
native Dutch speakers. The exclusion criteria were: (1) history or presence of 
an axis I psychiatric disorder (DSM-IV; assessed with the use of the Mini 
International Neuropsychiatric Interview; M.I.N.I: Lecrubier et al., 1997); (2) 
clinically significant medical disease; (3) use of psychotropic medication; (4) 
current or previous regular use of other drugs except cannabis (regular use 
defined as having used a drug more than four times in a lifetime); (5) abuse of 
alcohol (more than 14 units a week). Compliance with the inclusion and 
exclusion criteria was evaluated by means of self-report. Moreover, participants 
were required to abstain from chocolate, caffeine, and alcohol 12 hours before 
the experiment and not to use nicotine 2 hours before the session. Cannabis use 
was also not allowed within 2 days before the study. Subjects’ compliance with 
these criteria was evaluated by means of a personal interview and the 
application of a saliva drug test, which identified the recent use of cannabis, 
morphine or cocaine (Oral-View™ Saliva Multi-Drug of Abuse Test; Alfa 
Scientific Designs Inc., Poway, CA, U.S.A.). 
From the initial sample of 61 subjects, one male participant withdrew 
from the experiment before completing the flanker task, without providing any 
explanation. Another subject experienced anxiety before cannabis 
administration and had to quit the study. Regarding adverse events related to 
drug administration, one participant reported anxiety combined with fatigue 
and nausea, which led to his exclusion from the experiment. In addition, one 
female subject requested a break in the experiment, which prevented her from 
completing the flanker task. Moreover, the data of another participant was 
excluded from the analysis due to a technical malfunction. In addition, initial 
screening of the behavioral data revealed that there was one participant with 
an extremely low percentage (marked as extreme outlier in SPSS, <1st quartile 
minus 3.0 IQR) of correct trials. Consequently, this subject was excluded from 













The active drug substance was composed of the dried, milled and 
homogenized flowers of the plant Cannabis sativa (variety ‘Bedrocan’®; 19% 
THC). It was acquired from Bedrocan BV (Veendam, The Netherlands) where it 
was cultivated under standardized conditions in line with the requirements of 
Good Agricultural Practice (GAP). The placebo (variety ‘Bedrocan’®; <0.5% 
THC) administered in the experiment had a moisture content and terpenoid 
profile (providing the typical smell and taste of cannabis) matching the active 
drug. Study medication was prepared by ACE Pharmaceuticals BV (Zeewolde, 
The Netherlands). For each specific dose, precise amounts of active cannabis 
and placebo were mixed so that each dose was equal to 250 mg total weight but 
with varying concentrations of THC (placebo/5.5 mg/22 mg THC). Study 
medication was kept in a refrigerator (2–8°C) in triple-layer laminated foil 
pouches (Lamigrip). Shelf life stability was determined to be at least 1 year 
under these conditions. 
On the experiment day, each participant was administered a 
randomized single dose of cannabis by means of a Volcano® vaporizer 
(Storz&Bickel GmbH, Tüttlingen, Germany)—a safe and reliable method of 
intrapulmonary administration of THC (Hazekamp et al., 2006; Zuurman et al., 
2008). Cannabis was vaporized at a temperature of 230°C into a standard 
Volcano balloon as supplied with the vaporizer. For the purpose of blinding, the 
Volcano balloon was covered with a non-transparent plastic bag so that no 
differences in the density of the vapor were visible between dosages. 
When delivering THC by means of vaporizing, it should be noted that 
the dose present in the plant material is only partially vaporized into the 
balloon (Hazekamp et al., 2006), and that a part of the THC inhaled from the 
balloon is not absorbed by the lungs but is exhaled again (Zuurman et al., 2008). 
Therefore, in order to obtain an absorbed dose of approximately 2 and 8 mg of 
THC, we loaded the Volcano vaporizer with 5.5 and 22 mg of THC, respectively. 
Furthermore, since the Volcano vaporizer and cannabis joints deliver 
comparable amounts of THC (Abrams et al., 2007), the loaded vs. absorbed dose 
distinction can be applied to smoked cannabis as well.  
During administration, subjects were requested to inhale deeply and 
hold their breath for 10 seconds after each inhalation. They were asked not to 
speak during the inhalation period and were instructed to empty the balloon 
within 5 minutes. Subjects had the possibility to practice the inhalation 
procedure using an empty balloon before drug administration. 
 













Shortened Raven's Standard Progressive Matrices (SPM; measure of 
intelligence) 
Individual IQ test scores were evaluated by means of a reasoning-based 
intelligence test (Raven et al., 1988). Each element of this test is composed of a 
pattern or sequence of a diagrammatic puzzle with one item missing. The task 
is to complete the pattern or sequence by selecting the correct missing piece 
from a list of choices. The items become more difficult as the test taker 
proceeds through the test. The SPM test measures an individual's skill for 
creating perceptual relations and reasoning by analogy independent of 
language and formal schooling. The version of the test used in the experiment 
was composed of 14 items. 
 
Flanker task (error monitoring) 
In order to measure the ERN and Pe, an adapted version of the Flanker 
task was used (following Spronk et al., 2011). Subjects were instructed to 
respond with their right or left index finger to the letter they saw in the center 
of the screen (H or S), in a congruent (HHHHH or SSSSS) or incongruent 
(SSHSS or HHSHH) letter string. The assignment of H or S to the left or right 
index finger press was counterbalanced across subjects. A fixation point was 
initially presented (lasting 100 ms) with the stimulus following 300 ms later 
(lasting 100 ms). Afterwards the screen remained blank for 900 ms, followed by 
a visual feedback screen (lasting 1000 ms). The inter-trial interval was 100 ms. 
The visual feedback was composed of a yellow, blue, or red rectangle signaling 
that the previous response was correct, incorrect, or too late, respectively. 
Subjects were required to make a response as quick as possible to prevent 
feedback specifying that their reaction was too slow based on an individually 
determined preset reaction time (RT) deadline. Initially, the subjects were 
familiarized with the task in a practice block composed of 60 trials, during 
which the preliminary RT deadline was set at 800 ms. Afterwards, the average 
RT and SD of the correct responses were computed and the RT deadline was 
determined for each individual participant by adding 0.5 SD to the mean RT 
from the practice block. Consequently, this deadline was used during the main 
task. Note that the inclusion of this RT deadline is crucial to guarantee that 
error rates do not differ across the experimental conditions (see e.g. de Bruijn 
et al., 2004, 2006). The main task consisted of five blocks of 100 trials. After 
each part, subjects received information regarding the amount of incorrect and 
too late responses. Verbal instructions were provided to maintain response 
accuracy at around 80–90%. 




Visual analogue scales (VAS; subjective measure of drug effects)  
Three scales were used to measure the subjective effects of cannabis 
(horizontal 100-mm lines, the left pole labeled “not at all” and the right 
“extremely”) which refer to “(feeling) High”, “Good drug effect (pleasant)”, and 
“Bad drug effect (unpleasant)”. Participants were instructed to mark a point at 
the continuous scale in order to indicate their experience.  
 
EEG recording 
EEG activity was recorded over 10 positions: F1, Fz, F2, FC1, FCz, FC2, 
C1, Cz, C2, and Pz of the 10/10 standard. Bipolar derivations of electro-
oculogram (EOG) signals over the left and right outer canthus were used to 
calculate horizontal eye movements. Vertical eye movements were calculated 
by bipolar derivations of signals above and below the left eye. Monopolar 
recordings were referenced to the common mode sensor (CMS) and a driven 
right leg (DRL) electrode was used for drift correction (for details see 
http://www.biosemi.com/faq/cms&drl.htm). In order to re-reference the data 
offline, two electrodes were placed at the left and right mastoid. Signals were 
DC amplified and digitized with a BioSemi ActiveTwo system (BioSemi B.V., 
Amsterdam, The Netherlands) with a sampling rate of 512 Hz. 
 
Design and procedure 
The study used a randomized, double-blind, placebo-controlled, 
between-groups (placebo vs. 5.5 mg vs. 22 mg THC) design. All subjects were 
tested individually. After arrival, the participants were instructed to complete 
the SPM test within the time limit of 10 minutes. This was followed by the 
study drug administration. Six minutes after cannabis administration, subjects 
were instructed to report the subjective effects of the drug using the VAS. The 
evaluation of drug effects was then repeated twice–at 35 and 60 minutes after 
administration. After the initial VAS measurement, the subjects completed the 
Flanker task (in the time frame between 6 and 35 minutes after drug 
administration) on a computer using a Serial Response Box™ (Psychology 
Software Tools Inc., Sharpsburg, PA, U.S.A.).  
 
Statistical analysis 
Off-line analyses were conducted with Brain Vision Analyzer (Brain 
Products GmbH, Munich, Germany). After re-referencing the channels to the 
average mastoid, data was high-pass filtered at 0.01 Hz (24 dB/oct), and ocular 
artifacts correction was performed using the standard Gratton et al. (1983) 













method. EEG artifacts were automatically identified with the use of four 
criteria: (1) bad gradient (>50 µV/sample), (2) bad max–min difference (>200 
µV/200 ms), (3) bad amplitude (absolute value >1000 µV), and (4) low activity 
(<0.50 µV/100 ms). For the ERN and Pe components, epochs referring to correct 
and incorrect responses at incongruent trials were averaged individually and 
time-locked to response onset, starting 100 ms before and finishing 500 ms 
after the response, relative to a 100-ms pre-response baseline. In order to 
investigate if the impact of cannabis on the response-locked ERP components 
was not influenced by a general impairment of information processing or 
attention, additional stimulus-locked ERPs were analyzed (N1, N2, and P300). 
For these components, epochs associated with correct responses were averaged 
separately for congruent and incongruent stimuli time-locked to stimulus onset, 
starting 100 ms before and finishing 500 ms after the stimulus, relative to a 
100-ms pre-stimulus baseline. All ERPs were measured as the baseline-
corrected average amplitude across a predetermined interval, relative to the 
response or stimulus onset. The ERN amplitude was determined on correct and 
incorrect incongruent trials in the 50- to 100-ms time-window relative to 
response onset, at electrodes Fz, FCz, and Cz. The Pe was calculated on correct 
and incorrect incongruent trials in the period between 300 and 400 ms post-
response, at electrode Pz. The N1 amplitude was measured in the 65- to 115-ms 
time-window after stimulus onset, at electrodes FCz, Cz, and Pz. The N2 was 
determined in the period between 280 and 330 ms post-stimulus, at electrode 
FCz. The P300 amplitude was measured in the time-window between 350 and 
400 ms relative to stimulus onset, at electrodes FCz, Cz, and Pz.  
The response-locked ERN was analyzed with the use of a repeated-
measures ANOVA, with correctness (correct vs. incorrect) and electrode site (Fz 
vs. FCz vs. Cz) as within-subjects factors, and condition (placebo vs. 5.5 mg vs. 
22 mg THC) as a between-groups factor. A repeated-measures ANOVA was 
also used to analyze the Pe, with correctness (correct vs. incorrect) as a within-
subjects factor, and condition (placebo vs. 5.5 mg vs. 22 mg THC) as a between-
groups factor. In the case of the stimulus-locked ERPs, the data was analyzed 
with the use of a repeated-measures ANOVA, with congruency (congruent vs. 
incongruent) and electrode site (for N1 and P300 only; FCz vs. Cz vs. Pz) as 
within-subjects factors, and condition (placebo vs. 5.5 mg vs. 22 mg THC) as a 
between-groups factor. Moreover, repeated-measures ANOVAs were used to 
analyze individual means for RTs, with congruency (congruent vs. incongruent) 
and correctness (correct vs. incorrect) as within-subjects factors, and condition 
(placebo vs. 5.5 mg vs. 22 mg THC) as a between-groups factor. In the case of 




average error rates and percentage of “too late” responses, separate repeated-
measures ANOVAs were run for both measures, with congruency (congruent vs. 
incongruent) as a within-subjects factor, and condition (placebo vs. 5.5 mg vs. 
22 mg THC) as a between-groups factor. In addition, in order to investigate 
post-error slowing (Rabbitt, 1966), we used the optimized measure 
recommended by Dutilh et al. (2012) that compares RTs of correct responses 
preceding an error to RTs of correct responses following an error. Only 
incongruent trials were included in this analysis in order to circumvent serial 
congruency effects. Consequently, a repeated-measures ANOVA was applied 
with trial type (pre-error vs. post-error) as a within-subjects factor, and 
condition (placebo vs. 5.5 mg vs. 22 mg THC) as a between-groups factor.  
For the IQ test scores, age, and substance use data, between-groups 
ANOVAs were conducted with condition (placebo vs. 5.5 mg vs. 22 mg THC) as 
a between-groups factor. Data referring to sex was analyzed with the use of a 
Pearson's chi-squared test. VAS scores were analyzed by means of repeated-
measures ANOVAs with time after cannabis administration (6 vs. 35 vs. 60 
minutes) as a within-subjects factor, and condition as a between-groups factor. 
All measures were analyzed separately. Post-hoc multiple comparisons t-tests 
were applied with Bonferroni correction. A significance level of p < 0.05 was 




Demographic and substance use data 
No significant main effects of condition were found for age (F(2, 52) = 
1.478, p = 0.238), IQ test score (F(2, 52) = 0.5, p = 0.61), monthly cannabis use 
(F(2, 52) = 0.435, p = 0.649), years of cannabis exposure (F(2, 52) = 1.687, p = 
0.195), monthly alcohol use (F(2, 52) = 0.44, p = 0.647), monthly nicotine use 
(F(2, 52) = 1.034, p = 0.363), and years of nicotine exposure (F(2, 52) = 0.57, p = 
0.569). The drug conditions also did not significantly differ by sex (χ²(2, N = 55) 
= 3.524, p = 0.172). However, there was a significant main effect of condition on 
years of alcohol exposure (F(2, 52) = 3.918, p = 0.026); see Table 1. 
 
 













Table 1 Demographic and substance use data for each experimental condition. 
 Placebo 5.5 mg THC 22 mg THC 
Significance 
level 
N (Male : 
Female) 
 
19 (18 : 1) 18 (17 : 1) 18 (14 : 4) n.s. 
Age 21.3 (2.3) 21.1 (2.1) 22.3 (2.3) n.s. 
IQ test 
score 
8 (2.5) 7.3 (2.7) 7.1 (2.5) n.s. 
Monthly 
cannabis use 




5.8 (3.1) 4.8 (1.9) 6.3 (2.2) n.s. 
Monthly 
alcohol use 




5.5 (2.6) 4.8 (2.5) 7.2 (2.5) p = 0.026 
Monthly 
nicotine use 




4.5 (3.7) 3.5 (4.2) 4.8 (4.1) n.s. 
Standard deviations in parentheses; n.s.: non-significant difference; Age: reported in 
years; IQ test score: measured by a shortened version of Raven’s Standard Progressive 
Matrices; Monthly cannabis use: consumption of cannabis cigarettes (joints); Monthly 











The percentage of responses for each of the four response options for 
each trial type and each experimental group is presented in Table 2. The 
analysis revealed that error rate was higher in incongruent than in congruent 
trials (F(1, 52) = 234.172, p < 0.001). Likewise, there were more response 
omissions in incongruent than in congruent trials (F(1, 52) = 153.73, p < 0.001). 
Moreover, there was a significant main effect of condition on response 
omissions. Post-hoc multiple comparisons revealed that subjects in the 22 mg 
THC condition displayed more omissions than subjects in the placebo condition 
(t(35) = 3.828, p < 0.001) and the 5.5 mg THC condition (t(34) = 3.447, p = 
0.001). There were no significant interaction effects (p > 0.05). 
 
Table 2 Mean percentages of correct, incorrect, omission, and too early 
responses to congruent and incongruent trials for each experimental condition. 











% Correct 81.5 73.8 67 55.1 49.4 46.5 
% Incorrect 9.4 13.2 11.5 24.4 28.9 22.2 
% Omission 8 10.3 19.4 19 18.9 29.1 
% Too early 1.1 2.7 2.1 1.5 2.8 2.2 
 
Reaction times 
Trials with response omissions were excluded from the analysis (see 
Figure 1). The ANOVA revealed main effects of congruency (F(1, 52) = 66.188, p 
< 0.001) and correctness (F(1, 52) = 157.788, p < 0.001). Specifically, 
participants responded faster in congruent trials (299 ms) than in incongruent 
trial types (315 ms). Moreover, subjects performed faster in incorrect (288 ms) 
than correct trials (326 ms). There were no significant main effects of condition, 
or interaction effects (p > 0.05). 
 
 













Figure 1 Average reaction times for correct and incorrect responses in both 
congruent and incongruent trials for each experimental condition. Error bars 
represent SE of the mean. 
 
Post-error slowing 
A significant main effect of trial type (F(1, 52) = 24.408, p < 0.001) 
indicated that RTs following an incorrect response were significantly higher 
(328 ms) than those preceding an error (315 ms). There were no significant 
main effects of condition, or interaction effects (p > 0.05). 
 
Drug subjective effects 
A significant main effect of time after cannabis administration was 
found only in the case of the rating of “high” (with Huynh–Feldt correction; 
F(1.887, 94.358) = 18.063, p < 0.001). Nevertheless, significant main effects of 
condition were revealed on all three measures: “high” (F(2, 50) = 12.477, p < 
0.001), “good drug effect” (F(2, 50) = 11.097, p < 0.001), and “bad drug effect” 
(F(2, 50) = 4.918, p = 0.011). There were no significant interaction effects (p > 
0.05). 




Post-hoc multiple comparisons revealed that participants in the placebo 
condition showed significantly lower ratings of “high” than the 5.5 mg (t(35) = 
3.393, p = 0.001) and 22 mg THC groups did (t(35) = 4.732, p < 0.001); see 
Figure 2. Furthermore, the scores of “good drug effect” in the placebo group 
were significantly lower than those in the 5.5 mg (t(35) = 3.988, p < 0.001) and 
22 mg THC conditions (t(35) = 2.991, p = 0.009); see Figure 3. For the measures 
of “high” and “good drug effect”, no significant differences were obtained 
between the ratings in the 5.5 mg and 22 mg THC conditions (p > 0.05). In 
contrast, in the case of the ratings of “bad drug effect”, subjects in the 22 mg 
THC group displayed significantly elevated scores, compared to those in the 
placebo (t(35) = 2.882, p = 0.025) and 5.5 mg THC groups (t(34) = 2.923, p = 
0.025); see Figure 4. Moreover, the scores of “bad drug effect” did not 
significantly differ between the placebo and 5.5 mg THC groups (p > 0.05).  
Figure 2 Average subjective high (rated as a percentage) experienced in each 
experimental condition as a function of time after cannabis administration. 
Symbols indicate a significant (p < 0.01) difference between the 22 mg THC and 
placebo groups (*), and between the 5.5 mg THC and placebo groups (**). Error 
bars represent SE of the mean. 













Figure 3 Average subjective good drug effect (rated as a percentage) 
experienced in each experimental condition as a function of time after cannabis 
administration. Symbols indicate a significant (p < 0.01) difference between the 
22 mg THC and placebo groups (*), and between the 5.5 mg THC and placebo 
groups (**). Error bars represent SE of the mean. 
  




Figure 4 Average subjective bad drug effect (rated as a percentage) experienced 
in each experimental condition as a function of time after cannabis 
administration. Symbols indicate a significant (p < 0.05) difference between the 
placebo and 22 mg THC groups (*), and between the 5.5 mg and 22 mg THC 




The response-locked ERP components for the three drug conditions are 
displayed in Figure 5. A significant interaction was found between condition 
and correctness (F(2, 52) = 4.351, p = 0.018), but not between condition, 
electrode, and correctness (p > 0.05). There was also a significant interaction 
between electrode and correctness (F(2, 104) = 11.895, p < 0.001). In addition, 
significant main effects of electrode (F(2, 104) = 13.299, p < 0.001), correctness 
(F(1, 52) = 110.018, p < 0.001), and condition (F(2, 52) = 3.644, p = 0.033) were 
found. A separate between-groups ANOVA revealed that the main effect of 
condition was driven only by incorrect responses in the case of all three 
electrodes: Fz (F(2, 52) = 4.13, p = 0.022), FCz (F(2, 52) = 4.99, p = 0.01), and Cz 
(F(2, 52) = 5.768, p = 0.005).  














Figure 5 Grand average response-locked waveforms and topographical 
distributions of the difference between incorrect and correct responses at 
incongruent trials for each experimental condition. 
 




Post-hoc multiple comparisons of the ERN collapsed across the three 
electrodes (Fz, FCz, and Cz) showed that participants in the 22 mg THC 
condition displayed a significant decrease in amplitude of the ERN between 
correct and incorrect responses, as compared to placebo (t(35) = 2.915, p = 0.014; 
−3.4 vs. −7.1 µV), but not 5.5 mg THC (t(34) = 1.738, p = 0.333; −3.4 vs. −5.5 
µV). In addition, there was no significant difference between the 5.5 mg THC 
and placebo conditions (t(35) = 1.239, p = 0.595; −5.5 vs. −7.1 µV). 
 
Pe amplitude 
For the response-locked Pe amplitude, a significant interaction between 
condition and correctness was found (F(2, 52) = 5.184, p = 0.009). In addition, 
there was a main effect of correctness (F(1, 52) = 65.855, p < 0.001).  
Post-hoc multiple comparisons showed that participants in the 22 mg 
THC condition demonstrated a significant decrease in the amplitude of the Pe 
between correct and incorrect responses, as compared to placebo (t(35) = 2.909, 
p = 0.022; 2.8 vs. 6.2 µV), but not 5.5 mg THC (t(34) = 0.04, p = 1.0; 2.8 vs. 2.9 
µV). Moreover, subjects in the 5.5 mg THC condition significantly differed from 
those in the placebo condition with regard to this measure (t(35) = 2.615, p = 
0.024; 2.9 vs. 6.2 µV).  
 
N1 amplitude 
The stimulus-locked ERP components for the three drug conditions are 
presented in Figure 6. For the stimulus-locked N1 amplitude a main effect of 
electrode was found (F(2, 104) = 35.765, p < 0.001). There were no significant 
main effects of condition, or interaction effects (p > 0.05). 
 
N2 amplitude 
In the case of the stimulus-locked N2 amplitude, a main effect of 
congruency was revealed (F(1, 52) = 53.629, p < 0.001). There were no 
significant main effects of condition, or interaction effects (p > 0.05). 
 
P300 amplitude 
For the stimulus-locked P300 amplitude main effects of electrode (F(2, 
104) = 20.329, p < 0.001) and congruency were found (F(1, 52) = 32.769, p < 
0.001). There were no significant main effects of condition, or interaction effects 
(p > 0.05). 













Figure 6 Grand average stimulus-locked waveforms of the difference between 
congruent and incongruent trials at correct responses for each experimental 
condition.  
Discussion 
The present study shows for the first time that a low (5.5 mg THC) and 
high (22 mg THC) dose of vaporized cannabis differentially affects the neural 
correlates of error monitoring in frequent cannabis users. Specifically, a 
diminished ERN was observed in the high dose group in comparison to the 
placebo condition, whereas a diminished Pe amplitude was observed in both 
the high and low dose conditions, as compared to placebo. 




Based on the available research, the finding of a decreased ERN in the 
high dose condition allows the speculation that a high dose of cannabis might 
affect the transmission of a reinforcement learning signal to the ACC (Holroyd 
and Coles, 2002; but see Yeung et al., 2004). Furthermore, the observation of a 
reduced Pe in both the high and low dose groups may suggest that even a 
relatively low dose of cannabis is already sufficient to influence the late 
(elaborate) neural processing of errors as reflected in the Pe. Previous research 
has linked the Pe to conscious detection of errors (Nieuwenhuis et al., 2001; 
Endrass et al., 2005), and the temporal dynamics of the Pe have been directly 
correlated with the emergence of error awareness (Murphy et al., 2012). Based 
on this, it might be speculated that a low dose of cannabis is sufficient to affect 
error awareness, although such an assumption needs confirmation in future 
studies using independent behavioral measures. 
Moreover, whereas previous studies on the chronic effects of cannabis 
use have shown that users are typically tolerant to most of the detrimental 
effects of cannabis (Hart et al., 2001; Kelleher et al., 2004; D’Souza et al., 2008; 
Ramaekers et al., 2009; Hart et al., 2010; Theunissen et al., 2012), and recruit 
compensatory mechanisms to prevent performance being affected (Harding et 
al., 2012; Fridberg et al., 2013), we showed that acute administration of 
cannabis still impacts the neural correlates of processes involved in error 
monitoring. Accordingly, based on the current observations and on the 
assumption that the ERN and Pe reflect two dissociable processes involved in 
error monitoring (Nieuwenhuis et al., 2001), it may be assumed that the 
changes in the neural correlates of the error monitoring system observed in the 
current study are dose-dependent. Specifically, a high dose of cannabis seems 
to influence both the conscious (late) and the initial automatic processes 
involved in error monitoring, whereas a low dose of cannabis appears to affect 
only the conscious (late) processing of errors. 
These potential dose-dependent effects of cannabis on the error 
monitoring system suggested by our data are in line with an earlier study 
pointing to dose-dependent effects of cannabis on executive control functions 
(Ramaekers et al., 2006). In particular, cannabis has been shown to diminish 
performance on a task measuring executive control (Tower of London), with a 
high dose of cannabis (500 μg/kg body weight THC) leading to a more 
pronounced deterioration of performance than a low dose (250 μg/kg body 
weight THC; Ramaekers et al., 2006). Consequently, combining this with 
various dose-dependent effects of cannabis on neural correlates of cognitive 
functions and subjective effects (Hart et al., 2001; Hart et al., 2010; D’Souza et 













al., 2012; Hunault et al., 2014), one may speculate that the differential impact 
of the doses used in the current study reflects a dose-response relationship 
between cannabis and more general processes underlying executive function, 
including error monitoring.  
 
Limitations 
A significant limitation of the current study is its between-groups 
design, which at least theoretically raises the possibility that the observed 
differential impact of the cannabis doses was due to specific features of the 
studied sample. Another limitation was the lack of measurement of THC blood 
plasma levels, which did not allow us to assess the correlation between THC in 
the bloodstream and emergence of drug effects. In addition, the lack of this 
measurement makes it difficult to evaluate a dose–response curve, as it is 
possible that there were significant between-subjects differences in absorbed 
THC due to the lack of standardization of the duration and number of 
inhalations from the Volcano balloon. Furthermore, the application of a saliva 
test in order to verify the compliance of participants with the no-consumption 
criteria was not optimal, since it only provided an approximation of recent use 
of drugs. Evaluation of urinary levels of THC metabolites (11-COOH-THC) 
would have been a more accurate measure of drug use over an extended period 
of time. In addition, including a test for alcohol intoxication would have been 
another improvement in securing the compliance of subjects with the study 
requirements. Moreover, it is possible that the observed results were affected 
by the fact that some subjects could had been experiencing cannabis 
withdrawal symptoms on the day of testing, due to the requirement to be 
abstinent from cannabis for 2 days prior the study (Bonnet et al., 2014).  
 
Conclusion 
The results of this ERP study show that even a low dose of cannabis 
may have an effect on the neural correlates of error monitoring of frequent 
cannabis users. Furthermore, this impact is more pronounced with highly-
potent cannabis. Although any such speculations need to be confirmed by 
future studies, these observations raise the possibility that intoxicated frequent 
cannabis users might have difficulties to adapt to changing circumstances by 
monitoring and correcting their erroneous behavior. Consequently, it might be 
worthwhile to investigate the effects of using cannabis in situations which 
require flexible updating of behavior to changing conditions. Since such 
situations require efficient continuous error monitoring processes, any 




potential disturbances evoked by cannabis may lead to counterproductive, if 






The impact of cannabidiol on 
cognitive and emotional 
processing* 
  
                                                             
* This chapter is based on: 
 
Kowal MA, Hazekamp A, Colzato LS, van Steenbergen H, Hommel B (2013) 
Modulation of cognitive and emotional processing by cannabidiol: the role of the 
anterior cingulate cortex. Frontiers in Human Neuroscience 7. DOI: 
10.3389/fnhum.2013.00147 
 





Cannabis sativa is a plant containing over 70 active compounds called 
cannabinoids (Schoedel and Harrison, 2012). The psychoactive effects of 
cannabinoids are abused worldwide by about 20% of young people, who report 
regular or heavy use of the cannabis plant (Moore et al., 2007). Delta-9-
tetrahydrocannabinol (THC), the most prevalent cannabinoid in the plant, has 
been found to be responsible for producing most of the desirable effects of 
marijuana (Gaoni and Mechoulam, 1964). In line with that, the use of modern 
hydroponic cannabis farms has resulted in growing strains containing higher 
levels of THC, while keeping other cannabinoids at negligible levels (Hardwick 
and King, 2008). Accordingly, it may be assumed that the presence of THC-
dominated cannabis plants on the market leads to the risk of more severe 
consequences of abuse, since THC has been associated with induction of 
psychotic symptoms both in an acute intoxicated state (D’Souza et al., 2004) 
and in the long-term (Kuepper et al., 2010). Consequently, in the current paper 
we propose that cannabidiol (CBD), another abundant compound of cannabis, 
might have an impact on cognition and emotional processing, which is opposite 
to the effect of THC. Moreover, we suggest that the effects of CBD would be 
worth investigating in regard to the modulatory role of the anterior cingulate 
cortex (ACC)—a brain region where both affective and cognitive information 
converge (Bush et al., 2000; Botvinick et al., 2001; Paus, 2001). 
The pharmacology of CBD is well studied (for a review see: Mechoulam 
et al., 2002). Its effects are distinct and frequently opposite to those of THC 
(Fusar-Poli et al., 2012). Whereas THC is a cannabinoid receptor type 1 and 2 
(CB1r and CB2r) agonist, CBD has low affinity and a partially antagonistic 
effect at these receptors (Pertwee, 2008). Furthermore, CBD has been shown to 
be a serotonin receptor (5-HTr) agonist (Campos and Guimarães, 2008; 
Zanelati et al., 2010; Gomes et al., 2011). In recent years CBD has received 
renewed attention from researchers, mainly due to its anxiolytic (e.g. Zuardi et 
al., 1982; Zuardi et al., 1993; Crippa et al., 2004; Fusar-Poli et al., 2009; Crippa 
et al., 2011; Bergamaschi et al., 2011) and antipsychotic effects (e.g. Zuardi et 
al., 2009; Bhattacharyya et al., 2010; Schubart et al., 2011). The therapeutic 
value of CBD in clinical contexts is currently being explored (Zuardi et al., 2006; 
Zuardi et al., 2009; Hallak et al., 2010). Moreover, in a recent review Schier et 
al. (2012) suggested that CBD neither produces psychoactive effects, nor has an 
impact on cognition. In the light of up-to-date research, this claim may be 
considered unwarranted, since CBD has been shown to differ with THC in 













terms of activation of brain regions during tasks involving response inhibition 
(Borgwardt et al., 2008), emotional processing (Fusar-Poli et al., 2009), and 
verbal memory (Bhattacharyya et al., 2010). Additionally, as far as only the 
anxiolytic effect of CBD is considered, it may be assumed that it influences 
cognition through, for instance, reducing attention bias toward threatening 
stimuli (Bar-Haim et al., 2007). In spite of that, the effect of CBD on cognitive 
performance has been largely unexplored.  
Effect of CBD on the ACC 
CBD is associated with increased resting cerebral regional blood flow 
(rCBF) in the left parahippocampal gyrus and decreased rCBF in the 
amygdala-hippocampus complex, including the posterior cingulate cortex 
(Crippa et al., 2004). A functional neuroimaging (fMRI) study found evidence 
for attenuation of the blood-oxygen level dependent (BOLD) signal in the 
amygdala and the posterior and anterior cingulate cortex in response to the 
presentation of fearful faces, combined with a reduction in subjective anxiety 
(Fusar-Poli et al., 2009). CBD also disrupts the functional connectivity between 
the ACC and amygdala (Fusar-Poli et al., 2010). Taken together, these results 
point to both an anxiolytic effect of CBD and a critical modulatory role of the 
ACC. However, Bhattacharyya et al. (2010) found no effect of CBD on ACC 
activity in a task identical to the one used by Fusar-Poli et al. (2009)—a 
discrepancy we will be getting back to. To summarize, apart from the emotion-
regulating properties of CBD, the CBD–ACC relationship has not been 
systematically investigated.  
Accordingly, it would be worthwhile to examine how the impact of CBD 
on ACC activity may extend to the domain of cognitive performance. Since 
modulation of ACC activity is assumed to be the mechanism through which 
CBD affects brain connectivity during emotional processing (Fusar-Poli et al., 
2010), it might be suspected that the ACC is also the main target for CBD in 
terms of potential cognition-altering effects of the compound. Previous research 
has identified the ACC as an important relay station for cognitive control 
processes and as a region that integrates cognitive and emotional information 
(Bush et al., 2000; Botvinick et al., 2001; Paus, 2001). It is then possible that 
CBD has an effect on conflict monitoring—a process which monitors for the 
presence of conflicts in information processing. Conflict monitoring exerts top-
down control over information processing by focusing attention on task-




relevant processing streams, while blocking off task-irrelevant channels 
(Botvinick et al., 2001). In line with that, positron emission tomography (PET) 
and fMRI studies reliably show ACC activation in tasks in which subjects need 
to override automatic, but otherwise task-irrelevant responses, such as the 
Stroop Color Word Test (SCWT; Pardo et al., 1990; Carter et al., 1995; Bush et 
al., 1998) and go/no-go tasks (Casey et al., 1997; Kawashima et al., 1996). Since 
CBD has been shown to decrease activity in the ACC (Fusar-Poli et al., 2009; 
Fusar-Poli et al., 2010), it may be suspected that individuals treated with CBD 
are less likely to suppress their dominant response (Casey et al., 1997), or 
become aware of committing a mistake (Holroyd and Coles, 2002). 
 
Effect of CBD on cognition 
Taken together, research regarding the impact of CBD on ACC activity 
appears to be contradictory (see: Table 1): CBD has been reported to attenuate 
ACC activity (Fusar-Poli et al., 2009; Fusar-Poli et al., 2010), have no effect 
(Borgwardt et al., 2008; Bhattacharyya et al., 2009; Bhattacharyya et al., 2010), 
or even enhance ACC activity (Bhattacharyya et al., 2010). One possible 
explanation for these contradictory observations may be found in the type of 
tasks used in the studies mentioned and, thus, the functions which they relate 
to. In the case of cognition, keeping in mind the involvement of the ACC in 
conflict monitoring (Bush et al., 2000; Botvinick et al., 2001; Paus, 2001), it 
would be worthwhile to have a closer look at the findings of Bhattacharyya et 
al. (2010). The observed increased activity of the ACC during a verbal recall 
task is in line with research showing a lack of impairment of verbal memory in 
cannabis users intoxicated with high-CBD content cannabis (4.61% on average), 
as opposed to those who used low-CBD content plant material (0.08% on 
average; Morgan et al., 2010). Furthermore, it has been suggested that the 
memory-protective effect of CBD extends into the long-term (Morgan et al., 
2012). Combining the results of the above-mentioned studies, one could claim 
that the CBD-induced improvement is not restricted to the domain of memory 
itself, but reflects a more general enhancement of the conflict monitoring 
system.  













Table 1 Functional MRI studies of the cognitive and emotional effects of 
cannabidiol. 
* Contrasted with effects of delta-9-tetrahydrocannabinol (10 mg, 99.6 % pure) 
** Dynamic causal modeling – significant activation indicating a difference in the 
forward intrinsic connection between ACC and amygdala.  
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Additionally, such a claim becomes somewhat more plausible when one takes 
into account a recent investigation which found a trend for decreased response 
latency to oddball stimuli following CBD administration together with, 
surprisingly, an attenuating effect on the medial prefrontal cortex 
(Bhattacharyya et al., 2012). Although this opposite effect of CBD on activation 
and the finding of no effect of CBD on ACC activity in another study applying 
the verbal recall task make the case less clear (Bhattacharyya et al., 2009), it is 
possible that the beneficial effect of CBD is more visible in the case of 
modulating the deteriorating effects of THC than when administered alone. 
Since THC is a CB1r and CB2r agonist, the opposite, partially antagonistic, 
effect of CBD on CB1rs and CB2rs suggests that it may protect against the 
deterioration of cognitive performance caused by THC (Pertwee, 2008). THC 
has been shown to decrease the error-related negativity—an event-related 
potential indicative of conflict monitoring and assumed to be generated by the 
ACC (Spronk et al., 2011). Given the opposing neuropharmacological actions of 
the two compounds, one may then expect that CBD will inhibit the impact of 
THC on the ACC. On the other hand, in the absence of THC, partial 
antagonism of CB1rs might not be sufficient to produce overt changes in the 
conflict monitoring system, either at the behavioral or the neurophysiological 
level. Accordingly, it would be worthwhile to explore whether the THC-
protective effects of CBD can be related directly to ACC functioning.  
Effect of CBD on affective processing 
It is also interesting to consider the ACC-mediated impact of CBD on 
emotional processing. Animal research indicates that the anxiolytic effect of 
CBD depends on action of the compound on specific brain areas and that the 
effect could also, in some cases, be anxiogenic (Marco et al., 2011). In the case 
of human studies, it can be hypothesized that CBD decreases ACC activity, 
which would be in line with the anxiolytic effect of the compound (Fusar-Poli et 
al., 2009). The concurrent reduction in amygdala BOLD response associated 
with presentation of fearful faces gives further support to this assumption, 
given the involvement of this region in fear processing and its anatomical 
connection with the ACC (Fusar-Poli et al., 2009; Bhattacharyya et al., 2010; 
Fusar-Poli et al., 2010). However, while both Fusar-Poli et al. (2009) and 
Bhattacharyya et al. (2010) found a trend in reduction of subjective anxiety 
following CBD administration, only the former was able to observe a related 













decrease in ACC activation during emotional processing. In the case of the 
latter, the authors explain the lack of a possible effect by a selective analysis of 
brain areas where THC and CBD had opposite effects, instead of assessing the 
effects of the two compounds separately (Bhattacharyya et al., 2010). However, 
the fact that application of the same design, task, and subject sample led to 
different results throws some doubt on the importance of the ACC in mediating 
the effects of CBD on brain connectivity (Fusar-Poli et al., 2010). Moreover, if 
one were to follow the logic of Fusar-Poli et al. (2010) about top-down control of 
the ACC over the amygdala, attenuation of the amygdala BOLD response in 
the Bhattacharyya et al. (2010) study should not have been observed without a 
simultaneous effect in the ACC. In principle, the anxiolytic effects of CBD are 
assumed to be mediated by the ACC, which, in turn, affects activity of the 
amygdala (Fusar-Poli et al., 2010). Therefore, from this perspective, it is 
surprising that the reduction in subjective anxiety observed by Bhattacharyya 
et al. (2010) was indeed associated with a concurrent decrease in amygdala 
activation, but not the ACC. If the ACC actually plays a critical role in 
moderating the anxiolytic effects of CBD (Fusar-Poli et al., 2010), then it seems 
plausible to expect an effect in this brain region, even when keeping in mind 
the selective analysis of opposing effects of THC and CBD on activation 
(Bhattacharyya et al., 2010). On the other hand, the absence of an effect of 
CBD may alternatively be explained by the lack of a significant linear 
relationship between the effects of the two drugs and placebo. Consequently, 
the fact that Bhattacharyya et al. (2010) did not find CBD to be associated with 
decreased ACC activity is not necessarily equivalent to the lack of an effect of 
CBD relative to a placebo condition. In any case, apart from evidence pointing 
to a link between CBD and the ACC in emotional processing, it is likely that 
this connection is not as straightforward as suggested by Fusar-Poli et al. 
(2010).  
Summary 
In sum, existing research seems to undermine Schier’s et al. (2012) 
suggestion regarding the lack of a relationship between CBD and cognition. 
Rather, it seems that both cognitive and affective consequences of CBD 
administration may be mediated by the ACC. However, the lack of clear-cut 
results renders the extent and nature of this modulation unclear. The diversity 
of findings may be explained by various factors, including differential 




activation of the cognitive and affective subdivisions of the ACC (Bush et al., 
2000), the slow onset of action and inconsistent bioavailability of orally 
administered cannabinoids (Hazekamp et al., 2006), the dosage of CBD (Marco 
et al., 2011), or whether CBD was administered alone, or in combination with 
THC (Pertwee, 2008). Furthermore, since modulation of the cognitive effects of 
cannabinoids has been linked to polymorphism of the cannabinoid receptor 
(CNR1) gene (Ho et al., 2011; Stadelman et al., 2011), it is possible that some 
genetic predispositions of the studied samples could have influenced the results. 
From this perspective, also the catechol-O-methyltransferase (COMT) gene 
seems to be a plausible moderating factor due to its role in cognitive control 
(Colzato et al., 2010) and the pharmacological interactions between the 
endocannabinoid and dopamine systems (Fattore et al., 2010). In any case, 
inclusion of new variables could further clarify the CBD–ACC relationship and 
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Summary and general discussion 
In this thesis we investigated the acute, as well as chronic, effects of 
cannabis on the mechanisms underlying cognitive functions in a population of 
regular cannabis users. We carried out experiments in order to study the 
impact of cannabis on dopaminergic functioning, creative processes, and error 
monitoring. Moreover, we also reviewed the available scientific evidence 
regarding the effects of cannabidiol (CBD) on emotional and cognitive 
processing. 
First, the experiment presented in chapter 2 suggests that long-term 
cannabis use detrimentally affects dopaminergic functioning in the human 
stratum. The measurement of spontaneous eye-blink rate (EBR; a clinical 
marker of striatal dopamine [DA] transmission; Karson, 1983; Shukla, 1985; 
Taylor et al., 1999) among regular cannabis users and non-user controls with 
comparable demographic characteristics demonstrated a significant difference 
between the two groups. Specifically, cannabis users showed a decrease in their 
EBR, as compared to non-users. The results suggest that chronic cannabis use 
may impair dopaminergic transmission in the striatum indirectly through 
complex interactions with the endocannabinoid system (Hoffman et al., 2003; 
Fattore et al., 2010; Fernández-Ruiz et al., 2010).  
Second, the results presented in chapter 3 demonstrated impaired 
divergent thinking performance of regular cannabis users intoxicated with a 
high dose of delta-9-tetrahydrocannabinol (THC; 22 mg) in the form of 
vaporized herbal cannabis, as compared to users administered a low dose of 
THC (5.5 mg) or placebo. Divergent thinking occurs when trying to find as 
many solutions as possible to a problem without a clear definition (i.e. 
"brainstorming"). It is considered a mental process which is crucial to creative 
performance (Guilford, 1967) and linked to the functioning of striatal DA 
(Akbari Chermahini and Hommel, 2010). In the case of our study, although we 
considered the impaired creative performance of subjects as a possible 
consequence of induced distractibility due to supra-optimal levels of DA in the 
striatum (Cools and D'Esposito, 2011), this suggestion seems to be less likely in 
the light of new findings on DA and THC (Bossong et al., 2015). Future 
neuroimaging research is required to better understand the neural 
mechanisms underlying the effects of cannabinoids on divergent thinking and 
other related creative processes. It would be worthwhile to more thoroughly 
explore the link between cannabis and creativity, considering the widespread 














introduction of a motivational factor to a study might contribute to a higher 
ecological validity of its results. Specifically, if a cannabis user considers a 
creative task personally relevant, then the results of the task may provide a 
better representation of the creative performance of the subject outside the 
laboratory setting. This would be in line with anecdotal reports of cannabis 
users, who claim to use cannabis as a creativity-enhancer typically in 
situations which they find personally rewarding. 
Third, the experiment described in chapter 4 presented data on a dose-
dependent impact of vaporized cannabis on the neural correlates of error 
monitoring in chronic cannabis users. It was demonstrated that two event-
related potentials (ERPs) related to the recognition of discrepancies between 
expected and executed actions—the error-related negativity (ERN) and error 
positivity (Pe)—were differentially affected by the THC doses administered in 
the study. Specifically, a high dose of THC (22 mg) led to diminished ERN and 
Pe amplitudes in comparison to placebo, while a low THC dose (5.5 mg) 
resulted only in a reduced Pe amplitude, as compared to placebo. Moreover, 
there is evidence suggesting that the ERN and Pe represent separate processes 
involved in the monitoring of errors (Nieuwenhuis et al., 2001) and that the Pe 
is linked to the conscious awareness of errors (Nieuwenhuis et al., 2001, 
Endrass et al., 2005; Murphy et al., 2012). Consequently, we suggested that a 
high dose of cannabis influences both the initial automatic processing of errors 
and the conscious (late) error monitoring stages. Conversely, only the conscious 
(late) recognition of discrepancies between expected and executed actions 
appears to be affected by a low cannabis dose. Nevertheless, in order to confirm 
these assumptions, research including independent behavioral measures would 
be needed. Possibly, combining the acquisition of ERPs with the introduction of 
a manual response that indicates the awareness of committing an error by the 
subject could provide interesting information in this regard. 
Fourth, chapter 5 presented a review of available neuroimaging 
research on the effect of CBD on affective and cognitive processing. We 
reviewed evidence indicating a critical role of the anterior cingulate cortex 
(ACC) in this regard. The results were contradictory: CBD has been found to 
attenuate ACC activity (Fusar-Poli et al., 2009; Fusar-Poli et al., 2010), have no 
effect (Borgwardt et al., 2008; Bhattacharyya et al., 2009; Bhattacharyya et al., 
2010), or even enhance ACC activity (Bhattacharyya et al., 2010). Moreover, 
although the exact mechanism by which this occurs is unclear, we suggested 
that the modulation of ACC activity by CBD may lead to enhanced processing 
of errors due to a critical role of the ACC in this process (Bush et al., 2000; 




Botvinick et al., 2001; Paus, 2001; Shackman et al., 2011) and results 
suggesting an opposing effect of CBD on executive control functions, when 
compared with THC (Bhattacharyya et al., 2010; Morgan et al., 2010, 2012).  
Combining the information presented in chapters 4 and 5, it seems 
crucial to inquire into the relationship between cannabis and error monitoring 
in order to better understand the impact of using cannabis on everyday life. 
Specifically, since the lack of the ability to modify one's behavior in the face of 
changing circumstances and negative consequences is a core clinical symptom 
of drug dependence (Kalivas and Volkow, 2005), and deteriorated learning from 
errors is related to poor addiction treatment outcomes (Luo et al., 2013; Marhe 
et al., 2013), knowledge of the effects of cannabis on the capacity to detect and 
correct errors in one's behavior may be of importance in designing an effective 
addiction treatment program. Research on the long-term effects of using 
cannabis strongly suggests that the error monitoring capacity of regular users 
is impaired (Tapert et al., 2007; Hester et al., 2009; Falkenstein et al., 2013; 
Nicholls et al., 2015; Carey et al., 2015). Consequently, since the study 
presented in chapter 4 demonstrated that THC-rich cannabis may be 
detrimental to the processing of errors, it would be worthwhile to examine the 
supposedly contradictory effect of CBD on this process. Aside from the 
possibility that CBD may reduce the acute THC-induced impairment, it would 
be even more interesting to investigate whether the protective effect of CBD 
extends into the long-term, as suggested by some researchers (Morgan et al., 
2012). If that is the case, it might be worthwhile to explore the therapeutic 
application of CBD in the treatment of cannabis dependence. 
Nevertheless, it would be valuable to evaluate the findings presented in 
this thesis in the light of new evidence. In particular, up-to-date neuroimaging 
research indicates that regular cannabis use by adults does not lead to 
significant differences in DA D2/D3 receptor availability or DA release in the 
striatum (Stokes et al., 2012; Urban et al., 2012; Mizrahi et al., 2013; Volkow et 
al., 2014). On the other hand, Bloomfield et al. found deteriorated striatal DA 
synthesis capacity in cannabis users (2014a) and suggested this to be 
correlated with reduced reward sensitivity and reduced motivation associated 
with chronic cannabis use (2014b). Moreover, it has been suggested that the 
degree of impairment of dopaminergic transmission is positively correlated 
with the age of onset of cannabis use (Urban et al., 2012; Bloomfield et al., 
2014a). Consequently, neuroimaging studies on the effects of regular cannabis 














although we were able to find a robust reduction in the EBR of regular 
cannabis users, the results of our research require further investigation.  
However, a recent study by Bossong et al. (2015) re-analyzed the data 
of two previous studies on the acute effects of THC on DA transmission in the 
striatum (Bossong et al., 2009; Stokes et al., 2009). It was found that the 
increase in DA release after THC administration is modest, compared to that 
with other recreational drugs of abuse, like amphetamine or nicotine. Since 
THC administration leads to potent behavioral effects, it was suggested that 
these overt effects of the drug are unlikely to be exclusively dependent on 
striatal dopaminergic functioning. Possibly, the behavioral effects of THC may 
be mediated directly by the endocannabinoid system, although the exact 
mechanism by which this could occur is unclear (Bossong et al., 2015). In any 
case, taken together, the research on both the chronic and acute effects of 
cannabinoids on striatal DA suggests that cannabis may detrimentally affect 
the proper functioning of this neurotransmitter. On the other hand, a potential 
dopaminergic impairment is unlikely to be severe in the long-term. Possibly, 
the age of onset of cannabis use is a crucial aspect in this regard. Consequently, 
more research is needed to better understand the relationship between 
dopaminergic functioning of chronic cannabis users and the psychosis-inducing 
effects of cannabis (Kuepper et al., 2010).  
In summary, the mechanisms by which cannabis affects cognition and 
related neural functioning are complex and not yet fully understood. The 
pharmacological complexity of the cannabis plant and the widespread 
distribution of the endocannabinoid system in the human body, which interacts 
with other neuromodulatory systems in a variety of ways, seem to be the main 
factors contributing to this state of things. Combined with the legal limitations 
regarding the investigation of a prohibited drug, this complexity makes it 
difficult to study the effects of cannabis in any area, including cognition. 
Although more research is needed to identify the specific role of the 
endocannabinoid system in human cognition and the effect that cannabis has 
on this system and associated mental functions, the studies presented in the 
current thesis contribute to a better understanding of the various cognitive 

















Abdullaev Y, Posner MI, Nunnally R, Dishion TJ (2010) Functional MRI evidence 
for inefficient attentional control in adolescent chronic cannabis abuse. 
Behavioural Brain Research 215:45-57. 
Abrams DI, Vizoso HP, Shade SB, Jay C, Kelly ME, Benowitz NL (2007) 
Vaporization as a smokeless cannabis delivery system: a pilot study. 
Clinical Pharmacology and Therapeutics 82:572-578. 
Akbari Chermahini S, Hickendorff M, Hommel B (2012) Development and 
validity of a Dutch version of the Remote Associates Task: an item-
response theory approach. Thinking Skills and Creativity 7:177-186. 
Akbari Chermahini S, Hommel B (2010) The (b)link between creativity and 
dopamine: spontaneous eye blink rates predict and dissociate divergent 
and convergent thinking. Cognition 115:458-465 
Barbato G, Ficca G, Muscettola G, Fichele M, Beatrice M, Rinaldi F (2000) 
Diurnal variation in spontaneous eye-blink rate. Psychiatry Research 
93:145-151. 
Bar-Haim Y, Lamy D, Pergamin L, Bakermans-Kranenburg MJ, van IJzendoorn 
MH (2007) Threat-related attentional bias in anxious and nonanxious 
individuals: a meta-analytic study. Psychological Bulletin 133:1-24. 
Baumeister RF, Bratslavsky E, Muraven M, Tice DM (1998) Ego depletion: is the 
active self a limited resource?. Journal of Personality and Social 
Psychology 74:1252-1265. 
Bergamaschi MM, Queiroz RHC, Chagas MHN, de Oliveira DCG, De Martinis BS, 
Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, Martin-
Santos R, Hallak JEC, Zuardi AW, Crippa JAS (2011) Cannabidiol 
reduces the anxiety induced by simulated public speaking in treatment-
naive social phobia patients. Neuropsychopharmacology 36:1219-1226. 
Bhattacharyya S, Morrison PD, Fusar-Poli P, Martin-Santos R, Borgwardt S, 
Winton-Brown T, Nosarti C, O’Carroll C, Seal ML, Allen P, Mehta MA, 
Stone JM, Tunstall N, Giampietro V, Kapur S, Murray RM, Zuardi AW, 
Crippa JA, Atakan Z, Mcguire P K (2010) Opposite effects of delta-9-
tetrahydrocannabinol and cannabidiol on human brain function and 
psychopathology. Neuropsychopharmacology 35:764-774. 
Bhattacharyya S, Crippa JA, Allen P, Martin-Santos R, Borgwardt S, Fusar-Poli 
P, Rubia K, Kambeitz J, O’Carroll C, Seal M, Giampietro V, Brammer M, 
Zuardi AW, Atakan Z, McGuire PK (2012) Induction of psychosis by delta-
9-tetrahydrocannabinol reflects modulation of prefrontal and striatal 






Bhattacharyya S, Fusar-Poli P, Borgwardt S, Martin-Santos R, Nosarti C, 
O’Carroll C, Allen P, Seal ML, Fletcher PC, Crippa JA, Giampietro V, 
Mechelli A, Atakan Z, McGuire PL (2009) Modulation of mediotemporal 
and ventrostriatal function in humans by delta-9-tetrahydrocannabinol: a 
neural basis for the effects of Cannabis sativa on learning and psychosis. 
Archives of General Psychiatry 66:442-451. 
Bisogno T, Hanuš L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I, Moriello 
AS, Davis JB, Mechoulam R, Di Marzo V (2001) Molecular targets for 
cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors 
and on the cellular uptake and enzymatic hydrolysis of anandamide. 
British Journal of Pharmacology 134:845-852. 
Block RI, Farinpour R, Braverman K (1992) Acute effects of marijuana on 
cognition: relationships to chronic effects and smoking techniques. 
Pharmacology Biochemistry and Behavior 43:907-917. 
Bloomfield MAP, Morgan CJA, Egerton A, Kapur S, Curran HV, Howes OD (2014) 
Dopaminergic function in cannabis users and its relationship to cannabis-
induced psychotic symptoms. Biological Psychiatry 75:470-478. 
Bloomfield MAP, Morgan CJA, Kapur S, Curran HV, Howes OD (2014) The link 
between dopamine function and apathy in cannabis users: an [18F]-DOPA 
PET imaging study. Psychopharmacology 231:2251-2259. 
Bogacz R (2007) Optimal decision-making theories: linking neurobiology with 
behaviour. Trends in Cognitive Sciences 11:118-125. 
Bolla KI, Cadet J, London ED (1998) The neuropsychiatry of chronic cocaine 
abuse. The Journal of Neuropsychiatry & Clinical Neurosciences 10:280-
289. 
Bonnet U, Specka M, Stratmann U, Ochwadt R, Scherbaum N (2014) Abstinence 
phenomena of chronic cannabis-addicts prospectively monitored during 
controlled inpatient detoxification: cannabis withdrawal syndrome and its 
correlation with delta-9-tetrahydrocannabinol and -metabolites in serum. 
Drug and Alcohol Dependence 143:189-197. 
Borgwardt S, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, 
Fraccaro V, Atakan Z, Martin-Santos R, O’Carroll C, Rubia K, McGuire 
PK (2008) Neural basis of delta-9-tetrahydrocannabinol and cannabidiol: 
effects during response inhibition. Biological Psychiatry 64:966-973. 
Bossong MG, Mehta MA, van Berckel BNM, Howes OD, Kahn RS, Stokes PRA 
(2015) Further human evidence for striatal dopamine release induced by 
administration of delta-9-tetrahydrocannabinol (THC): selectivity to 





Bossong MG, van Berckel BNM, Boellaard R, Zuurman L, Schuit RC, Windhorst 
AD, van Gerven JMA, Ramsey NF, Lammertsma AA, Kahn RS (2009) 
Delta 9-tetrahydrocannabinol induces dopamine release in the human 
striatum. Neuropsychopharmacology 34:759-766. 
Botvinick MM, Braver TS, Barch DM, Carter CS, Cohen JD (2001) Conflict 
monitoring and cognitive control. Psychological Review 108:624-652. 
Bourassa M, Vaugeois P (2001) Effects of marijuana use on divergent thinking. 
Creativity Research Journal 13:411-416. 
Bush G, Luu P, Posner MI (2000) Cognitive and emotional influences in anterior 
cingulate cortex. Trends in Cognitive Sciences 4:215-222. 
Bush G, Whalen PJ, Rosen BR, Jenike MA, McInerney SC, Rauch SL (1998) The 
counting Stroop: an interference task specialized for functional 
neuroimaging: validation study with functional MRI. Human Brain 
Mapping 6:270-282. 
Campos AC, Guimarães FS (2008) Involvement of 5HT1A receptors in the 
anxiolytic-like effects of cannabidiol injected into the dorsolateral 
periaqueductal gray of rats. Psychopharmacology 199:223-230. 
Carey SE, Nestor L, Jones J, Garavan H, Hester R (2015) Impaired learning from 
errors in cannabis users: dorsal anterior cingulate cortex and 
hippocampus hypoactivity. Drug and Alcohol Dependence 155:175-182. 
Carter CS, Mintun M, Cohen JD (1995) Interference and facilitation effects 
during selective attention: an H215O PET study of Stroop task 
performance. NeuroImage 2:264-272. 
Casey BJ, Trainor RJ, Orendi JL, Schubert AB, Nystrom LE, Giedd JN, 
Castellanos FX, Haxby JV, Noll DC, Cohen JD, Forman SD, Dahl RE, 
Rapoport JL (1997) A developmental functional MRI study of prefrontal 
activation during performance of a go-no-go task. Journal of Cognitive 
Neuroscience 9:835-847. 
Colzato LS, Hommel B (2008) Cannabis, cocaine, and visuomotor integration: 
evidence for a role of dopamine D1 receptors in binding perception and 
action. Neuropsychologia 46:1570-1575. 
Colzato LS, Ozturk A, Hommel B (2012) Meditate to create: the impact of focused-
attention and open-monitoring training on convergent and divergent 
thinking. Frontiers in Psychology 3:116. 
Colzato LS, Szapora A, Pannekoek JN, Hommel B (2013) The impact of physical 
exercise on convergent and divergent thinking. Frontiers in Human 
Neuroscience 7:824. 





eye blink rates in recreational cocaine users: evidence for dopaminergic 
hypoactivity. PLoS ONE 3:e3461. 
Colzato LS, Waszak F, Nieuwenhuis S, Posthuma D, Hommel B (2010) The 
flexible mind is associated with the catechol-O-methyltransferase (COMT) 
Val158Met polymorphism: evidence for a role of dopamine in the control 
of task-switching. Neuropsychologia 48:2764-2768. 
Cools R, D'Esposito M (2011) Inverted-U-shaped dopamine actions on human 
working memory and cognitive control. Biological Psychiatry 69:e113-
e125. 
Cools R, Frank MJ, Gibbs SE, Miyakawa A, Jagust W, D'Esposito M (2009) 
Striatal dopamine predicts outcome-specific reversal learning and its 
sensitivity to dopaminergic drug administration. Journal of Neuroscience 
29:1538-1543. 
Crane NA, Schuster RM, Gonzalez R (2013) Preliminary evidence for a sex-
specific relationship between amount of cannabis use and neurocognitive 
performance in young adult cannabis users. Journal of the International 
Neuropsychological Society 19:1009-1015. 
Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-
Santos R, Simoes MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, Filho AS, 
Freitas-Ferrari MC, McGuire PK, Zuardi AW, Busatto GF, Hallak JEC 
(2011) Neural basis of anxiolytic effects of cannabidiol (CBD) in 
generalized social anxiety disorder: a preliminary report. Journal of 
Psychopharmacology 25:121-130. 
Crippa JA, Zuardi AW, Garrido GE, Wichert-Ana L, Guarnieri R, Ferrari L, 
Azevedo-Marques PM, Hallak JEC, McGuire PK, Busatto GF (2004) 
Effects of cannabidiol (CBD) on regional cerebral blood flow. 
Neuropsychopharmacology 29:417-426. 
Curran HV, Brignell C, Fletcher S, Middleton P, Henry J (2002) Cognitive and 
subjective dose-response effects of acute oral delta-9-
tetrahydrocannabinol (THC) in infrequent cannabis users. 
Psychopharmacology (Berl) 164:61-70. 
Curran HV, Morgan CJA (2014) Desired and undesired effects of cannabis on the 
human mind and psychological well-being. In: Handbook of Cannabis, 1st 
ed. (Pertwee R, ed). Oxford: Oxford University Press. 
de Bruijn ERA, Hulstijn W, Verkes RJ, Ruigt GSF, Sabbe BGC (2004) Drug-
induced stimulation and suppression of action monitoring in healthy 
volunteers. Psychopharmacology 177:151-160. 





antipsychotic and antidepressant drugs on action monitoring in healthy 
volunteers. Brain Research 1105:122-129. 
De Dreu CKW, Baas M, Nijstad BA (2008) Hedonic tone and activation level in 
the mood-creativity link: toward a dual pathway to creativity model. 
Journal of Personality and Social Psychology 94:739-756. 
De Dreu CKW, Nijstad BA, Baas M, Wolsink I, Roskes M (2012) Working memory 
benefits creative insight, musical improvisation, and original ideation 
through maintained task-focused attention. Personality and Social 
Psychology Bulletin 38:656-669. 
Debener S, Ullsperger M, Siegel M, Fiehler K, von Cramon DY, Engel AK (2005) 
Trial-by-trial coupling of concurrent electroencephalogram and functional 
magnetic resonance imaging identifies the dynamics of performance 
monitoring. Journal of Neuroscience 25:11730-11737. 
Deuschel G, Goddemeier C (1998) Spontaneous and reflex activity of facial 
muscles in dystonia, Parkinson's disease, and in normal subjects. Journal 
of Neurology, Neurosurgery & Psychiatry 64:320-324. 
Devane WA, Dysarz FA, Johnson MR, Melvin LS, Howlett AC (1988) 
Determination and characterization of a cannabinoid receptor in rat brain. 
Molecular Pharmacology 34:605-613. 
Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, 
Mandelbaum A, Etinger A, Mechoulam R (1992) Isolation and structure of 
a brain constituent that binds to the cannabinoid receptor. Science 
258:1946-1949. 
Dreisbach G, Müller J, Goschke T, Strobel A, Schulze K, Lesch KP, Brocke B 
(2005) Dopamine and cognitive control: the influence of spontaneous 
eyeblink rate and dopamine gene polymorphisms on perseveration and 
distractibility. Behavioral Neuroscience 119:483-490. 
D'Souza DC, Fridberg DJ, Skosnik PD, Williams A, Roach B, Singh N, Carbuto M, 
Elander J, Schnakenberg A, Pittman B, Sewell RA, Ranganathan M, 
Mathalon D (2012) Dose-related modulation of event-related potentials to 
novel and target stimuli by intravenous delta-9-THC in humans. 
Neuropsychopharmacology 37:1632-1646. 
D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, 
Gueorguieva R, Krystal JH (2004) The psychotomimetic effects of 
intravenous delta-9-tetrahydrocannabinol in healthy individuals: 
implications for psychosis. Neuropsychopharmacology 29:1558-1572. 
D'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, 





of delta-9-tetrahydrocannabinol in frequent users of cannabis. 
Neuropsychopharmacology 33:2505-2516. 
Dutilh G, van Ravenzwaaij D, Nieuwenhuis S, van der Maas HLJ, Forstmann BU, 
Wagenmakers EJ (2012) How to measure post-error slowing: a confound 
and a simple solution. Journal of Mathematical Psychology 56:208-216. 
Earleywine M (2002) Understanding marijuana. Oxford: Oxford University Press. 
ElSohly M, Gul W (2014) Constituents of Cannabis sativa. In: Handbook of 
Cannabis, 1st ed. (Pertwee R, ed). Oxford: Oxford University Press. 
Endrass T, Franke C, Kathmann N (2005) Error awareness in a saccade 
countermanding task. Journal of Psychophysiology 19:275-280. 
Eriksen BA, Eriksen CW (1974) Effects of noise letters upon the identification of 
a target letter in a nonsearch task. Perception & Psychophysics 16:143-
149. 
Falkenstein M, Hohnsbein J, Hoormann J, Blanke L (1990) Effects of errors in 
choice reaction tasks on the ERP under focused and divided attention. In: 
Psychophysiological Brain Research, 1st ed. (Brunia C, Gaillard A, Kok A, 
ed), pp 192-195. Tilburg: Tilburg University Press. 
Falkenstein M, Hoormann J, Christ S, Hohnsbein J (2000) ERP components on 
reaction errors and their functional significance: a tutorial. Biological 
Psychology 51:87-107. 
Fattore L, Melis M, Fadda P, Pistis M, Fratta W (2010) The endocannabinoid 
system and nondrug rewarding behaviours. Experimental Neurology 
224:23-36. 
Fernández-Ruiz J, Hernández M, Ramos JA (2010) Cannabinoid-dopamine 
interaction in the pathophysiology and treatment of CNS disorders. CNS 
Neuroscience & Therapeutics 16:e72-e91. 
Freed W (1980) Eye-blink rates and platelet monoamine oxidase activity in 
chronic schizophrenic patients. Biological Psychiatry 15:329-332. 
Fridberg DJ, Skosnik PD, Hetrick WP, O’Donnell BF (2013) Neural correlates of 
performance monitoring in chronic cannabis users and cannabis-naive 
controls. Journal of Psychopharmacology 27:515-525. 
Friendly M (2014) Power. Power analysis for ANOVA designs Available at: 
http://www.math.yorku.ca/scs/online/power [Accessed February 26, 2015]. 
Fusar-Poli P, Allen P, Bhattacharyya S, Crippa JA, Mechelli A, Borgwardt S, 
Martin-Santos R, Seal ML, O’Carrol C, Atakan Z, Zuardi AW, McGuire 
PK (2010) Modulation of effective connectivity during emotional 
processing by Δ9-tetrahydrocannabinol and cannabidiol. The 





Fusar-Poli P, Crippa JA, Bhattacharyya S, Borgwardt S, Allen P, Martin-Santos 
R, Seal ML, Surguladze SA, O’Carrol C, Atakan Z, Zuardi AW, McGuire 
PK (2009) Distinct effects of delta-9-tetrahydrocannabinol and 
cannabidiol on neural activation during emotional processing. Archives of 
General Psychiatry 66:95-105. 
Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an 
active constituent of hashish. Journal of the American Chemical Society 
86:1646-1647. 
Gehring WJ, Goss B, Coles MGH, Meyer DE, Donchin E (1993) A neural system 
for error detection and compensation. Psychological Science 4:385-390. 
Gerdeman GL, Partridge JG, Lupica CR, Lovinger DM (2003) It could be habit 
forming: drugs of abuse and striatal synaptic plasticity. Trends in 
Neurosciences 26:184-192. 
Gomes FV, Resstel LBM, Guimarães FS (2011) The anxiolytic-like effects of 
cannabidiol injected into the bed nucleus of the stria terminalis are 
mediated by 5-HT1A receptors. Psychopharmacology 213:465-473. 
Gratton G, Coles MGH, Donchin E (1983) A new method for off-line removal of 
ocular artifact. Electroencephalography and Clinical Neurophysiology 
55:468-484. 
Green B, Kavanagh D, Young R (2003) Being stoned: a review of self-reported 
cannabis effects. Drug and Alcohol Review 22:453-460. 
Grotenhermen F (2003) Pharmacokinetics and pharmacodynamics of 
cannabinoids. Clinical Pharmacokinetics 42:327-360. 
Guilford JP (1967) The nature of human intelligence. New York: McGraw-Hill. 
Hallak JEC, Machado-de-Sousa JP, Crippa JA, Sanches RF, Trzesniak C, Chaves 
C, Bernardo SA, Regalo SC, Zuardi AW (2010) Performance of 
schizophrenic patients in the Stroop Color Word Test and electrodermal 
responsiveness after acute administration of cannabidiol (CBD). Revista 
Brasileira de Psiquiatria 32:56-61. 
Harding IH, Solowij N, Harrison BJ, Takagi M, Lorenzetti V, Lubman DI, Seal 
ML, Pantelis C, Yücel M (2012) Functional connectivity in brain networks 
underlying cognitive control in chronic cannabis users. 
Neuropsychopharmacology 37:1923-1933. 
Hardwick S, King LA (2008) Home office cannabis potency study. Home Office 
Scientific Development Branch. 
Hart CL, Ilan AB, Gevins A, Gunderson EW, Role K, Colley JA, Foltin RW (2010) 
Neurophysiological and cognitive effects of smoked marijuana in frequent 





Hart CL, van Gorp W, Haney M, Foltin RW, Fischman MW (2001) Effects of 
acute smoked marijuana on complex cognitive performance. 
Neuropsychopharmacology 25:757-765. 
Hazekamp A, Ruhaak R, Zuurman L, van Gerven JMA, Verpoorte R (2006) 
Evaluation of a vaporizing device (Volcano®) for the pulmonary 
administration of tetrahydrocannabinol. Journal of Pharmaceutical 
Sciences 95:1308-1317. 
Herrmann MJ, Römmler J, Ehlis AC, Heidrich A, Fallgatter AJ (2004) Source 
localization (LORETA) of the error-related-negativity (ERN/Ne) and 
positivity (Pe). Cognitive Brain Research 20:294-299. 
Hester R, Nestor L, Garavan H (2009) Impaired error awareness and anterior 
cingulate cortex hypoactivity in chronic cannabis users. 
Neuropsychopharmacology 34:2450-2458. 
Hindocha C, Freeman TP, Schafer G, Gardener C, Das RK, Morgan CJ, Curran 
HV (2015) Acute effects of delta-9-tetrahydrocannabinol, cannabidiol and 
their combination on facial emotion recognition: A randomised, double-
blind, placebo-controlled study in cannabis users. European 
Neuropsychopharmacology 25:325-334. 
Hirvonen J, Goodwin RS, Li CT, Terry GE, Zoghbi SS, Morse C, Pike VW, Volkow 
ND, Huestis MA, Innis RB (2012) Reversible and regionally selective 
downregulation of brain cannabinoid CB1 receptors in chronic daily 
cannabis smokers. Molecular Psychiatry 17:642-649. 
Ho BC, Wassink TH, Ziebell S, Andreasen NC (2011) Cannabinoid receptor 1 
gene polymorphisms and marijuana misuse interactions on white matter 
and cognitive deficits in schizophrenia. Schizophrenia Research 128:66-75. 
Hoffman AF, Oz M, Caulder T, Lupica CR (2003) Functional tolerance and 
blockade of long-term depression at synapses in the nucleus accumbens 
after chronic cannabinoid exposure. Journal of Neuroscience 23:4815-4820. 
Holroyd CB, Coles MGH (2002) The neural basis of human error processing: 
reinforcement learning, dopamine, and the error-related negativity. 
Psychological Review 109:679-709. 
Hommel B (2012) Convergent and divergent operations in cognitive search. In: 
Cognitive search: evolution, algorithms, and the brain, 1st ed. (Todd P, 
Hills T, Robbins T, ed), pp 221-235. Cambridge, MA: MIT Press. 
Hunault CC, Böcker KBE, Stellato RK, Kenemans JL, de Vries I, Meulenbelt J 
(2014) Acute subjective effects after smoking joints containing up to 69 
mg delta-9-tetrahydrocannabinol in recreational users: a randomized, 





Inzlicht M, Schmeichel BJ (2012) What is ego depletion? Toward a mechanistic 
revision of the resource model of self-control. Perspectives on 
Psychological Science 7:450-463. 
Kalivas PW, Volkow ND (2005) The neural basis of addiction: a pathology of 
motivation and choice. American Journal of Psychiatry 162:1403-1413. 
Karson CN (1983) Spontaneous eye-blink rates and dopaminergic systems. Brain 
106:643-653. 
Kawashima R, Satoh K, Itoh H, Ono S, Furumoto S, Gotoh R, Koyama M, 
Yoshioka S, Takahashi T, Takahashi K, Yanagisawa T, Fukuda H (1996) 
Functional anatomy of go/no-go discrimination and response selection: a 
PET study in man. Brain Research 728:79-89. 
Kelleher LM, Stough C, Sergejew AA, Rolfe T (2004) The effects of cannabis on 
information-processing speed. Addictive Behaviors 29:1213-1219. 
Kleven MS, Koek W (1996) Differential effects of direct and indirect dopamine 
agonists on eye blink rate in cynomolgus monkeys. Journal of 
Pharmacology and Experimental Therapeutics 279:1211-1219. 
Kowal MA, Colzato LS, Hommel B (2011) Decreased spontaneous eye blink rates 
in chronic cannabis users: evidence for striatal cannabinoid-dopamine 
interactions. PLoS ONE 6:e26662. 
Kowal MA, Hazekamp A, Colzato LS, van Steenbergen H, van der Wee NJA, 
Durieux J, Manai M, Hommel B (2015) Cannabis and creativity: highly 
potent cannabis impairs divergent thinking in regular cannabis users. 
Psychopharmacology 232:1123-1134. 
Kowal MA, Hazekamp A, Colzato LS, van Steenbergen H, Hommel B (2013) 
Modulation of cognitive and emotional processing by cannabidiol: the role 
of the anterior cingulate cortex. Frontiers in Human Neuroscience 7. 
Kowal M, van Steenbergen H, Colzato LS, Hazekamp A, van der Wee NJA, Manai 
M, Durieux J, Hommel B (2015) Dose-dependent effects of cannabis on 
the neural correlates of error monitoring in frequent cannabis users. 
European Neuropsychopharmacology 25:1943-1953. 
Kuepper R, Ceccarini J, Lataster J, van Os J, van Kroonenburgh M, van Gerven 
JMA, Marcelis M, Van Laere K, Henquet C (2013) Delta-9-
tetrahydrocannabinol-induced dopamine release as a function of psychosis 
risk: 18F-fallypride positron emission tomography study. PLoS ONE 
8:e70378. 
Kuepper R, Morrison PD, van Os J, Murray RM, Kenis G, Henquet C (2010) Does 
dopamine mediate the psychosis-inducing effects of cannabis? A review 






Lecrubier Y, Sheehan DV, Weiller E, Amorim P, Bonora I, Harnett Sheehan K, 
Janavs J, Dunbar G (1997) The Mini International Neuropsychiatric 
Interview (MINI). A short diagnostic structured interview: reliability and 
validity according to the CIDI. European Psychiatry 12:224-231. 
Luo X, Zhang S, Hu S, Bednarski SR, Erdman E, Farr OM, Hong KI, Sinha R, 
Mazure CM, Li CSR (2013) Error processing and gender-shared and -
specific neural predictors of relapse in cocaine dependence. Brain 
136:1231-1244. 
Marco E, Garcia-Gutierrez MS, Bermudez-Silva FJ, Moreira FA, Guimarães FS, 
Manzanares J, Viveros MP (2011) Endocannabinoid system and 
psychiatry: in search of a neurobiological basis for detrimental and 
potential therapeutic effects. Frontiers in Behavioral Neuroscience 5:63. 
Marhe R, Luijten M, van de Wetering BJM, Smits M, Franken IHA (2013) 
Individual differences in anterior cingulate activation associated with 
attentional bias predict cocaine use after treatment. 
Neuropsychopharmacology 38:1085-1093. 
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of 
a cannabinoid receptor and functional expression of the cloned cDNA. 
Nature 346:561-564. 
McDonald J, Schleifer L, Richards JB, de Wit H (2003) Effects of THC on 
behavioral measures of impulsivity in humans. 
Neuropsychopharmacology 28:1356-1365. 
McPartland J, Russo E (2014) Non-phytocannabinoid constituents of cannabis 
and herbal synergy. In: Handbook of Cannabis, 1st ed. (Pertwee R, ed). 
Oxford: Oxford University Press. 
Mechoulam R, Parker LA, Gallily R (2002) Cannabidiol: an overview of some 
pharmacological aspects. Journal of Clinical Pharmacology 42:11-19. 
Mednick S (1962) The associative basis of the creative process. Psychological 
Review 69:220-232. 
Mink JW (1996) The basal ganglia: focused selection and inhibition of competing 
motor programs. Progress in Neurobiology 50:381-425. 
Mizrahi R, Suridjan I, Kenk M, George TP, Wilson A, Houle S, Rusjan P (2013) 
Dopamine response to psychosocial stress in chronic cannabis users: a 
PET study with [11C]-(+)-PHNO. Neuropsychopharmacology 38:673-682. 
Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis 
G (2007) Cannabis use and risk of psychotic or affective mental health 





Morgan CJA, Freeman TP, Schafer GL, Curran HV (2010) Cannabidiol 
attenuates the appetitive effects of delta-9-tetrahydrocannabinol in 
humans smoking their chosen cannabis. Neuropsychopharmacology 
35:1879-1885. 
Morgan CJA, Gardener C, Schafer G, Swan S, Demarchi C, Freeman TP, 
Warrington P, Rupasinghe I, Ramoutar A, Tan N, Wingham G, Lewis S, 
Curran HV (2012) Sub-chronic impact of cannabinoids in street cannabis 
on cognition, psychotic-like symptoms and psychological well-being. 
Psychological Medicine 42:391-400. 
Morgan CJA, Schafer G, Freeman TP, Curran HV (2010) Impact of cannabidiol on 
the acute memory and psychotomimetic effects of smoked cannabis: 
naturalistic study. The British Journal of Psychiatry 197:285-290. 
Murphy PR, Robertson IH, Allen D, Hester R, O’Connell RG (2012) An 
electrophysiological signal that precisely tracks the emergence of error 
awareness. Frontiers in Human Neuroscience 6:65. 
Nicholls C, Bruno R, Matthews A (2015) Chronic cannabis use and ERP 
correlates of visual selective attention during the performance of a flanker 
go/nogo task. Biological Psychology 110:115-125. 
Nieuwenhuis S, Ridderinkhof KR, Blom J, Band GPH, Kok A (2001) Error-related 
brain potentials are differentially related to awareness of response errors: 
evidence from an antisaccade task. Psychophysiology 38:752-760. 
Nijstad BA, De Dreu CKW, Rietzschel EF, Baas M (2010) The dual pathway to 
creativity model: creative ideation as a function of flexibility and 
persistence. European Review of Social Psychology 21:34-77. 
Pardo JV, Pardo PJ, Janer KW, Raichle ME (1990) The anterior cingulate cortex 
mediates processing selection in the Stroop attentional conflict paradigm. 
Proceedings of the National Academy of Sciences 87:256-259. 
Paus T (2001) Primate anterior cingulate cortex: where motor control, drive and 
cognition interface. Nature Reviews Neuroscience 2:417-424. 
Pertwee RG (2008) The diverse CB1 and CB2 receptor pharmacology of three 
plant cannabinoids: delta-9-tetrahydrocannabinol, cannabidiol and delta-
9-tetrahydrocannabivarin. The British Journal of Pharmacology 153:199-
215. 
Quik M, Chen L, Parameswaran N, Xie X, Langston JW, McCallum SE (2006) 
Chronic oral nicotine normalizes dopaminergic function and synaptic 
plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned 
primates. The Journal of Neuroscience 26:4681-4689. 





of Experimental Psychology 71:264-272. 
Ramaekers JG, Kauert G, Theunissen EL, Toennes SW, Moeller MR (2008) 
Neurocognitive performance during acute THC intoxication in heavy and 
occasional cannabis users. Journal of Psychopharmacology 23:266-277. 
Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, 
Moeller MR (2006) High-potency marijuana impairs executive function 
and inhibitory motor control. Neuropsychopharmacology 31:2296-2303. 
Raven JC, Court JH, Raven J (1988) Manual for Raven’s progressive matrices 
and vocabulary scales. London: Lewis. 
Runco MA (2007) Creativity: theories, themes, and issues. San Diego, CA: 
Academic Press. 
Russell JA, Weiss A, Mendelsohn GA (1989) Affect grid: a single-item scale of 
pleasure and arousal. Journal of Personality and Social Psychology 
57:493-502. 
Russo EB (2011) Taming THC: potential cannabis synergy and phytocannabinoid-
terpenoid entourage effects. British Journal of Pharmacology 163:1344-
1364. 
Schafer GL, Feilding A, Morgan CJA, Agathangelou M, Freeman TP, Curran HV 
(2012) Investigating the interaction between schizotypy, divergent 
thinking and cannabis use. Consciousness and Cognition 21:292-298. 
Schier ARM, Ribeiro NPO, Silva ACO, Hallak JEC, Crippa JA, Nardi AE, Zuardi 
AW (2012) Cannabidiol, a Cannabis sativa constituent, as an anxiolytic 
drug. Revista Brasileira de Psiquiatria 34:104-117. 
Schoedel KA, Harrison SJ (2012) Subjective and physiological effects of 
oromucosal sprays containing cannabinoids (nabiximols): potentials and 
limitations for psychosis research. Current Pharmaceutical Design 
18:5008-5014. 
Schubart CD, Sommer IE, van Gastel WA, Goetgebuer RL, Kahn RS, Boks MP 
(2011) Cannabis with high cannabidiol content is associated with fewer 
psychotic experiences. Schizophrenia Research 130:216-221. 
Schulz S, Arning L, Pinnow M, Wascher E, Epplen JT, Beste C (2012) When 
control fails: influence of the prefrontal but not striatal dopaminergic 
system on behavioural flexibility in a change detection task. 
Neuropharmacology 62:1028-1033. 
Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK (2007) 
Individual differences in reward responding explain placebo-induced 
expectations and effects. Neuron 55:325-336. 





Placebo and nocebo effects are defined by opposite opioid and 
dopaminergic responses. Archives of General Psychiatry 65:220-231. 
Shackman AJ, Salomons TV, Slagter HA, Fox AS, Winter JJ, Davidson RJ (2011) 
The integration of negative affect, pain and cognitive control in the 
cingulate cortex. Nature Reviews Neuroscience 12:154-167. 
Shou-Zhong Y (1997) The divine farmer's materia medica: a translation of the 
Shen Nong Ben Cao Jing. Boulder, CO: Blue Poppy Press. 
Shukla D (1985) Blink rate as clinical indicator. Neurology 35:286. 
Spronk D, Dumont GJH, Verkes RJ, de Bruijn ERA (2011) Acute effects of delta-
9-tetrahydrocannabinol on performance monitoring in healthy volunteers. 
Frontiers in Behavioral Neuroscience 5:59. 
Stadelmann AM, Juckel G, Arning L, Gallinat J, Epplen JT, Roser P (2011) 
Association between a cannabinoid receptor gene (CNR1) polymorphism 
and cannabinoid-induced alterations of the auditory event-related P300 
potential. Neuroscience Letters 496:60-64. 
Stemmer B, Segalowitz SJ, Witzke W, Schönle PW (2004) Error detection in 
patients with lesions to the medial prefrontal cortex: an ERP study. 
Neuropsychologia 42:118-130. 
Stokes PR, Egerton A, Watson B, Reid A, Lappin J, Howes OD, Nutt DJ, 
Lingford-Hughes AR (2012) History of cannabis use is not associated with 
alterations in striatal dopamine D2/D3 receptor availability. Journal of 
Psychopharmacology 26:144-149. 
Stokes PR, Mehta MA, Curran HV, Breen G, Grasby PM (2009) Can recreational 
doses of THC produce significant dopamine release in the human 
striatum?. NeuroImage 48:186-190. 
Tapert SF, Schweinsburg AD, Drummond SPA, Paulus MP, Brown SA, Yang TT, 
Frank LR (2007) Functional MRI of inhibitory processing in abstinent 
adolescent marijuana users. Psychopharmacology 194:173-183. 
Tart CT (1970) Marijuana intoxication: common experiences. Nature 226:701-704. 
Taylor JR, Elsworth JD, Lawrence MS, Sladek JR, Roth RH, Redmond DE (1999) 
Spontaneous blink rates correlate with dopamine levels in the caudate 
nucleus of MPTP-treated monkeys. Experimental Neurology 158:214-220. 
Theunissen EL, Kauert GF, Toennes SW, Moeller MR, Sambeth A, Blanchard 
MM, Ramaekers JG (2012) Neurophysiological functioning of occasional 
and heavy cannabis users during THC intoxication. Psychopharmacology 
220:341-350. 
Tinklenberg JR, Darley CF, Roth WT, Pfefferbaum A, Kopell BS (1978) 





and Mental Disease 166:362-364. 
Torrance EP (1966) Torrance tests of creative thinking-norms. Lexington, MA: 
Personal Press. 
Ullsperger M, Fischer AG, Nigbur R, Endrass T (2014) Neural mechanisms and 
temporal dynamics of performance monitoring. Trends in Cognitive 
Sciences 18:259-267. 
Urban NBL, Slifstein M, Thompson JL, Xu X, Girgis RR, Raheja S, Haney M, 
Abi-Dargham A (2012) Dopamine release in chronic cannabis users: a 
[11c]raclopride positron emission tomography study. Biological Psychiatry 
71:677-683. 
Volkow ND, Wang GJ, Telang F, Fowler JS, Alexoff D, Logan J, Jayne M, Wong C, 
Tomasi D (2014) Decreased dopamine brain reactivity in marijuana 
abusers is associated with negative emotionality and addiction severity. 
Proceedings of the National Academy of Sciences 111:E3149-E3156. 
Weckowicz TE, Fedora O, Mason J, Radstaak D, Bay KS, Yonge KA (1975) Effect 
of marijuana on divergent and convergent production cognitive tests. 
Journal of Abnormal Psychology 84:386-398. 
Yeung N, Botvinick MM, Cohen JD (2004) The neural basis of error detection: 
conflict monitoring and the error-related negativity. Psychological Review 
111:931-959. 
Zanelati TV, Biojone C, Moreira FA, Guimarães FS, Joca SRL (2010) 
Antidepressant-like effects of cannabidiol in mice: possible involvement of 
5-HT1A receptors. British Journal of Pharmacology 159:122-128. 
Zenasni F, Lubart T (2011) Pleasantness of creative tasks and creative 
performance. Thinking Skills and Creativity 6:49-56. 
Zuardi AW, Cosme RA, Graeff FG, Guimarães FS (1993) Effects of ipsapirone and 
cannabidiol on human experimental anxiety. Journal of 
Psychopharmacology 7:82-88. 
Zuardi AW, Crippa JA, Hallak JEC, Pinto JP, Chagas MHN, Rodrigues GGR, 
Dursun SM, Tumas V (2009) Cannabidiol for the treatment of psychosis 
in Parkinson's disease. Journal of Psychopharmacology 23:979-983. 
Zuardi AW, Hallak JEC, Dursun SM, Morais SL, Sanches RF, Musty RE, Crippa 
JA (2006) Cannabidiol monotherapy for treatment-resistant 
schizophrenia. Journal of Psychopharmacology 20:683-686. 
Zuardi AW, Shirakawa I, Finkelfarb E, Karniol IG (1982) Action of cannabidiol on 
the anxiety and other effects produced by delta-9-THC in normal subjects. 
Psychopharmacology 76:245-250. 





Verpoorte R, Pinquier JL, Cohen AF, van Gerven JMA (2008) Effect of 
intrapulmonary tetrahydrocannabinol administration in humans. Journal 



















Samenvatting en algemene discussie 
In dit proefschrift onderzoeken we zowel de acute als de chronische 
effecten van cannabis op de mechanismen die ten grondslag liggen aan 
cognitieve functies, in een populatie van regelmatige gebruikers van cannabis. 
We voerden experimenten uit met als doel de impact te bepalen van cannabis 
op dopamine-gerelateerde functies, creatieve processen en error monitoring in 
het brein. Daarnaast voerden we een literatuur review uit naar de effecten van 
cannabidiol (CBD) op emotionele en cognitieve processen.  
Ten eerste suggereren onze experimenten, zoals beschreven in 
hoofdstuk 2, dat lange-termijngebruik van cannabis een schadelijk effect heeft 
op het dopaminerge functioneren van het striatum. Metingen van de spontane 
oogknipper-frequentie (eye blink rate, EBR; een klinische marker voor striatale 
dopamine (DA) transmissie; Karson, 1983; Shukla, 1985; Taylor et al., 1999) 
onder regelmatige cannabisgebruikers liet een significant verschil zien ten 
opzichte van een controlegroep bestaande uit niet-gebruikers met vergelijkbare 
demografische karakteristieken. De cannabisgebruikers toonden een duidelijke 
afname van EBR, in vergelijking met de controlegroep. Deze resultaten 
suggereren dat chronisch cannabisgebruik een verstorend effect heeft op de 
dopaminerge transmissie in het striatum. Dit gebeurt mogelijk indirect door 
complexe interacties met het endocannabinoidsysteem (Hoffman et al., 2003; 
Fattore et al., 2010; Fernández-Ruiz et al., 2010).  
Ten tweede toont dit proefschrift, in hoofdstuk 3, hoe regelmatige 
cannabisgebruikers verstoord divergent thinking performance vertonen na 
toediening van een hoge dosis delta-9-tetrahydrocannabinol (THC; 22 mg) in de 
vorm van verdampte cannabis, in verhouding tot een toediening van een lage 
dosis THC (5.5 mg) of een placebo. Divergent denken vind plaats wanneer men 
probeert om zoveel mogelijk antwoorden te formuleren op een vraag zonder 
duidelijke definitie (ook wel bekend als ‘brainstormen’). Dit wordt beschouwd 
als een mentaal proces dat cruciaal is voor creatieve prestaties (Guilford, 1967) 
en is waarschijnlijk gelinkt aan het functioneren van DA in het striatum 
(Akbari Chermahini and Hommel, 2010). Hoewel we in eerste instantie 
dachten dat de verstoorde creatieve prestatie van onze studiepersonen een 
mogelijk gevolg was van geïnduceerde afleiding van de geest door verminderde 
DA spiegels in het striatum (Cools and D'Esposito, 2011), lijkt deze verklaring 
minder waarschijnlijk in het licht van meer recente bevindingen over DA en 
THC (Bossong et al., 2015). Toekomstig neuro-imaging onderzoek kan ons 





effecten van cannabinoiden op divergent denken en verwante creatieve 
processen. Het is zeker de moeite waard om verder te kijken naar de 
verhouding tussen cannabis en creativiteit, gezien het wijdverbreide geloof dat 
cannabis werkt als inspiratiebron voor creativiteit (e.g. Green et al., 2005). 
Wellicht zou het introduceren van een motiverende factor aan de studieopzet 
kunnen bijdragen aan een hogere relevantie van de studieresultaten; wanneer 
een cannabisgebruiker een creatieve taak als persoonlijk relevant beschouwd, 
dan is het waarschijnlijk dat de resultaten van die taak een realistischer 
representatie geven van de creatieve performance van die persoon buiten de 
studieopzet. Dit is dan meer in lijn met anekdotische verhalen van 
cannabisgebruikers, die claimen dat het gebruik van cannabis als verbeteraar 
van creativiteit met name werkt in situaties die ze persoonlijk plezierig vinden. 
In de derde plaats toont ons onderzoek, volgens de resultaten in 
hoofdstuk 4, een dosis-afhankelijk effect van verdampte cannabis op de neurale 
correlaten van error monitoring bij chronische cannabisgebruikers. Er kon 
worden aangetoond dat twee event-related potentials (ERPs) die gerelateerd 
zijn aan het herkennen van discrepanties tussen verwachte en uitgevoerde 
acties – namelijk de error-related negativity (ERN) en error positivity (Pe) – 
verschillend werden beïnvloed door de THC doses die werden toegediend in de 
studie. Zo leidde de hoge THC dosis (22 mg) tot een vermindering van ERN en 
Pe amplitude in vergelijking met placebo, terwijl een lage dosis THC (5.5 mg) 
resulteerde in alleen een vermindering van Pe amplitude, ten opzichte van 
placebo. Er is bewijs dat de ERN en Pe verschillende neurale processen 
vertegenwoordigen die betrokken zijn bij het monitoren van fouten maken 
(Nieuwenhuis et al., 2001) en dat de Pe betrokken is bij het bewust ervaren van 
fouten (Nieuwenhuis et al., 2001, Endrass et al., 2005; Murphy et al., 2012). Op 
basis hiervan stellen wij voor dat een hoge dosis cannabis een invloed heeft op 
zowel het initiële automatische (onbewuste) proces van verwerken van fouten, 
als ook op de latere (en bewuste) fases van foutverwerking. De lage dosis THC, 
daarentegen, beïnvloed enkel de bewuste, late, herkenning van de discrepantie 
tussen de verwachte en de uitgevoerde actie. Om deze aannames verder te 
bevestigen moet aanvullend onderzoek worden gedaan waarbij gedrag bij 
proefpersonen meer uitvoerig wordt bestudeerd naar deze aspecten. Goede 
aanvullende informatie zou kunnen worden verkregen door een studieopzet 
waarbij het meten van ERPs wordt gecombineerd met een manuele respons die 
de bewustheid kan meten voor het begaan van een fout door het studieobject.  
In de vierde plaats (hoofdstuk 5) geeft dit proefschrift een overzicht van 





neuro-imaging onderzoek betreffende de effecten van CBD op affectieve en 
cognitieve processing. In deze review komt er een belangrijke rol naar voren 
voor de antrior cingulate cortex (ACC). De resultaten van de besproken studies 
spreken elkaar tegen: CBD lijkt de activiteit van de ACC te kunnen 
verminderen (Fusar-Poli et al., 2009; Fusar-Poli et al., 2010), heeft geen effect 
(Borgwardt et al., 2008; Bhattacharyya et al., 2009; Bhattacharyya et al., 2010), 
of kan ACC activiteit juist bevorderen (Bhattacharyya et al., 2010). Hoewel het 
mechanisme waarop deze effecten plaatsvinden niet bekend is, suggereren we 
in ons hoofdstuk dat de modulatie van ACC activiteit door CBD kan leiden tot 
een verbeterde verwerking van fouten vanwege de cruciale rol die de ACC 
speelt bij dit proces (Bush et al., 2000; Botvinick et al., 2001; Paus, 2001; 
Shackman et al., 2011) en vanwege het tegengestelde effect van CBD op 
executive control functies, in vergelijking met THC (Bhattacharyya et al., 2010; 
Morgan et al., 2010, 2012).  
Wanneer we de resultaten van hoofdstuk 4 en 5 combineren, dan blijkt 
het belang om de relatie tussen cannabisgebruik en error monitoring verder te 
bestuderen, en zo de invloed van cannabis op het dagelijks functioneren van 
subjecten beter te kunnen begrijpen. Gezien het aangetaste vermogen om 
gedrag aan te passen onder invloed van veranderende omstandigheden en 
negatieve consequenties een centraal klinisch symptoom is van drugverslaving 
(Kalivas and Volkow, 2005), en gezien het feit dat een verminderd vermogen 
om te leren van fouten is gerelateerd aan slechte prognoses bij behandeling van 
drugverslaving (Luo et al., 2013; Marhe et al., 2013), lijkt het van belang om 
meer kennis te verzamelen over de effecten van cannabis op iemands 
vaardigheid om fouten te detecteren en te corrigeren. Dit kan vervolgens 
helpen bij het opstellen van een effectief behandelprogramma voor 
drugverslaving. Onderzoek naar de lange-termijn effecten van cannabisgebruik 
suggereert sterk dat het vermogen tot error monitoring bij regelmatige 
gebruikers van cannabis verstoord is (Tapert et al., 2007; Hester et al., 2009; 
Falkenstein et al., 2013; Nicholls et al., 2015; Carey et al., 2015). Als gevolg 
hiervan, en gezien de resultaten van hoofdstuk 4 die aantoonden dat THC-rijke 
cannabis negatieve invloed kan hebben op het verwerken van fouten, verdient 
het aanbeveling om verder te kijken naar het verwachtte tegengestelde effect 
van CBD op dit proces. Afgezien van de mogelijkheid dat CBD direct de door 
THC veroorzaakte verslechtering zou kunnen tegengaan, is het wellicht nog 
interessanter om te onderzoeken of het beschermende effect van CBD ook op de 





dit zo zijn, dan ontstaat er een mogelijke therapeutische rol voor CBD bij de 
behandeling van cannabisverslaving. 
Het is de moeite waard om de bevindingen van dit proefschrift verder 
te evalueren, in het licht van recente nieuwe ontdekkingen. Geavanceerd 
neuro-imaging onderzoek laat zien dat regelmatig cannabisgebruik bij 
volwassen niet leidt tot significante verschillen in dopamine D2/D3 receptor 
beschikbaarheid of de aanmaak van dopamine in het striatum (Stokes et al., 
2012; Urban et al., 2012; Mizrahi et al., 2013; Volkow et al., 2014). Daar 
tegenover staat onderzoek van Bloomfield et al. (2014a) waarbij een afgenomen 
DA synthese capaciteit in het striatum werd gevonden bij cannabisgebruikers, 
hetgeen de studie in verband brengt met een verminderde gevoeligheid van het 
beloningsysteem en met verminderde motivatie bij chronische 
cannabisgebruikers. Bovendien is er gesuggereerd dat de mate van 
verslechtering van dopaminerge transmissie positief is gecorreleerd met de 
leeftijd waarop met cannabis consumptie is begonnen (Urban et al., 2012; 
Bloomfield et al., 2014a). Als gevolg hiervan zijn neuro-imaging studies naar de 
effecten van regelmatig cannabis gebruik op dopaminergic functioning niet 
doorslaggevend. Vanuit dit perspectief zijn de resultaten van onze eigen studie, 
hoewel we een robuuste vermindering zagen van EBR in regelmatige 
cannabisgebruikers, helaas niet volledig eenduidig. 
Een recente studie door Bossong et al. (2015) combineert en her-
analyseert de gegevens van twee eerdere studies naar de acute effecten van 
THC toediening op DA transmissie in het striatum (Bossong et al., 2009; 
Stokes et al., 2009). Daarbij bleek dat de toename van DA afgifte na THC 
toediening beperkt is, vergeleken bij andere recreatief gebruikte drugs zoals 
amfetamine of nicotine. Omdat THC toediening leidt tot potente 
gedragseffecten, suggereren de onderzoekers dat deze overduidelijke effecten 
van cannabis waarschijnlijk niet alleen veroorzaakt worden door dopaminergic 
functioning van het striatum. Het is ook mogelijk dat de effecten van THC op 
gedrag op directe wijze gemedieerd worden door het endocannabinoidsysteem, 
hoewel het exacte mechanisme waardoor dat zou moeten gebeuren nog 
onduidelijk is (Bossong et al., 2015). Wetenschappelijk onderzoek naar 
chronische maar ook acute effecten van cannabinoiden op striatale DA wijst in 
het algemeen op een verstorend effect op het normale functioneren van deze 
neurotransmitter. Toch is het niet waarschijnlijk dat een verstoring van de 
dopaminerge werking op langere termijn desastreuze gevolgen heeft. Wellicht 
is hierbij de leeftijd waarop voor het eerst cannabis is gebruikt een cruciale 





relatie tussen dopaminergic functioning bij chronische cannabis gebruikers en 
de psychose-inducerende effecten van cannabis (Kuepper et al., 2010).  
Samengevat moeten we concluderen dat de mechanismen waarlangs 
cannabis een invloed heeft op cognitie en verwante neurale functies complex 
zijn, en slechts deels begrepen. Belangrijke redenen die hiervoor zijn aan te 
wijzen zijn de farmacologische complexiteit van de cannabis plant zelf, maar 
ook de wijdverspreide aanwezigheid van het endocannabinoidsysteem in het 
menselijk lichaam, welke interactie heeft met andere neuromodulaire systemen 
op allerlei verschillende wijzen. In combinatie met de vele wettelijke restricties 
die rusten op onderzoek met de verboden drug Cannabis, zorgt dit voor een 
uiterst complexe situatie waarin het lastig blijft om de effecten van cannabis te 
onderzoeken, ook op cognitie. We hopen dat toekomstig onderzoek in staat zal 
zijn om te bepalen welke rol het endocannabinoidsysteem heeft bij menselijke 
cognitie, en wat voor effect cannabis heeft op dit systeem en de daarmee 
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